<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Magnesium for treating sickle cell disease - Than, NN - 2019 | Cochrane Library</title> <meta content="Magnesium for treating sickle cell disease - Than, NN - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011358.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Magnesium for treating sickle cell disease - Than, NN - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011358.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011358.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Magnesium for treating sickle cell disease" name="citation_title"/> <meta content="Nan Nitra Than" name="citation_author"/> <meta content="Faculty of Medicine, Melaka‐Manipal Medical College (MMMC), Manipal Academy of Higher Education(MAHE)" name="citation_author_institution"/> <meta content="nannitra@gmail.com" name="citation_author_email"/> <meta content="Htoo Htoo Kyaw Soe" name="citation_author"/> <meta content="Faculty of Medicine, Melaka‐Manipal Medical College, Manipal Academy of Higher Education (MAHE)" name="citation_author_institution"/> <meta content="Senthil K Palaniappan" name="citation_author"/> <meta content="NHS trust" name="citation_author_institution"/> <meta content="Adinegara BL Abas" name="citation_author"/> <meta content="Melaka‐Manipal Medical College (Manipal Academy of Higher Education)" name="citation_author_institution"/> <meta content="Lucia De Franceschi" name="citation_author"/> <meta content="University of Verona‐AOUI Verona" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD011358.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/09/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011358.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011358.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011358.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anemia, Sickle Cell [blood, *drug therapy]; Antisickling Agents [*therapeutic use]; Hydroxyurea [therapeutic use]; Magnesium [blood, *therapeutic use]; Magnesium Sulfate [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011358.pub3&amp;doi=10.1002/14651858.CD011358.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="tIsQXAzh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011358\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011358\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ms","ja","fa","fr","de","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011358.pub3",title:"Magnesium for treating sickle cell disease",firstPublishedDate:"Sep 9, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011358.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011358.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011358.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011358.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011358.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011358.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011358.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011358.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011358.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011358.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3012 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011358.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-sec-0108"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-sec-0102"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/appendices#CD011358-sec-0113"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/table_n/CD011358StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/table_n/CD011358StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Magnesium for treating sickle cell disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/information#CD011358-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Nan Nitra Than</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/information#CD011358-cr-0003">Htoo Htoo Kyaw Soe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/information#CD011358-cr-0004">Senthil K Palaniappan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/information#CD011358-cr-0005">Adinegara BL Abas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011358.pub3/information#CD011358-cr-0006">Lucia De Franceschi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/information/en#CD011358-sec-0117">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 September 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011358.pub3">https://doi.org/10.1002/14651858.CD011358.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011358-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011358-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011358-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011358-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011358-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011358-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011358-abs-0001" lang="en"> <section id="CD011358-sec-0001"> <h3 class="title" id="CD011358-sec-0001">Background</h3> <p>Sickle cell disease is an autosomal recessive inherited haemoglobinopathy which causes painful vaso‐occlusive crises due to sickle red blood cell dehydration. Vaso‐occlusive crises are common painful events responsible for a variety of clinical complications; overall mortality is increased and life expectancy decreased compared to the general population. Experimental studies suggest that intravenous magnesium has proven to be well‐tolerated in individuals hospitalised for the immediate relief of acute (sudden onset) painful crisis and has the potential to decrease the length of hospital stay. Some in vitro studies and open studies of long‐term oral magnesium showed promising effect on pain relief but failed to show its efficacy. The studies show that oral magnesium therapy may prevent sickle red blood cell dehydration and prevent recurrent painful episodes. There is a need to access evidence for the impact of oral and intravenous magnesium effect on frequency of pain, length of hospital stay and quality of life. This is an updated version of the review. </p> </section> <section id="CD011358-sec-0002"> <h3 class="title" id="CD011358-sec-0002">Objectives</h3> <p>To evaluate the effects of short‐term intravenous magnesium on the length of hospital stay and quality of life in children and adults with sickle cell disease. To determine the effects of long‐term oral magnesium therapy on the frequency of painful crises and the quality of life in children and adults with sickle cell disease. </p> </section> <section id="CD011358-sec-0003"> <h3 class="title" id="CD011358-sec-0003">Search methods</h3> <p>We searched the Cochrane Haemoglobinopathies Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. </p> <p>Date of last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group’s Haemoglobinopathies Trials Register: 03 February 2019. </p> <p>Date of last search of other resources (clinical trials registries): 04 April 2019.</p> </section> <section id="CD011358-sec-0004"> <h3 class="title" id="CD011358-sec-0004">Selection criteria</h3> <p>We searched for published and unpublished randomized controlled studies of oral or intravenous magnesium compared to placebo or no magnesium. </p> </section> <section id="CD011358-sec-0005"> <h3 class="title" id="CD011358-sec-0005">Data collection and analysis</h3> <p>Authors independently assessed the study quality and extracted the data using standard Cochrane methodologies. </p> </section> <section id="CD011358-sec-0006"> <h3 class="title" id="CD011358-sec-0006">Main results</h3> <p>We included five randomized placebo‐controlled studies with a total of 386 participants (aged three to 53 years). Of these, two shorter parallel studies (n = 306) compared intravenous magnesium sulphate to placebo (normal saline) for admission to hospital due to a vaso‐occlusive crisis, for which we were able to analyse data. The quality of evidence was moderate for studies in this comparison, mainly due to limitations due to risk of bias and imprecision. Two of the three longer‐term studies comparing oral magnesium pidolate to placebo had a cross‐over design. The third was a parallel factorial study which compared hydroxyurea and oral magnesium to each other and to placebo over a longer period of time; we only present the comparison of oral magnesium to placebo from this study. The quality of evidence was very low with uncertainty of the estimation. </p> <p>The eight‐hourly dose levels in the two studies of intravenous magnesium were different; one used 100 mg/kg while the second used 40 mg/kg. Only one of these studies (n = 104) reported the mean daily pain score while hospitalised (a non‐significant difference between groups, moderate quality evidence). The second study (n = 202) reported a number of child‐ and parent‐reported quality of life scores. None of the scores showed any difference between treatment groups (low quality evidence). Data from one study (n = 106) showed no difference in length of stay in hospital between groups (low quality evidence). Both studies reported on adverse events, but not defined by severity as we had planned. One study showed significantly more participants receiving intravenous magnesium experienced warmth at infusion site compared to placebo; there were no differences between groups for other adverse events (low quality evidence). </p> <p>Three studies (n = 80) compared oral magnesium pidolate to placebo. None of them reported data which we were able to analyse. One study (n = 24) reported on the number of painful days and stated there was no difference between two groups (low quality evidence). None of the studies reported on quality of life or length of hospital stay. Two studies (n = 68) reported there were no differences in levels of magnesium in either plasma or red blood cells (moderate quality evidence). Two studies (n = 56) reported adverse events. One reported episodes of mild diarrhoea and headache, all of which resolved without stopping treatment. The second study reported adverse events as gastrointestinal disorders, headache or migraine, upper respiratory infections and rash; which were all evenly distributed across treatment groups (moderate quality evidence). </p> </section> <section id="CD011358-sec-0007"> <h3 class="title" id="CD011358-sec-0007">Authors' conclusions</h3> <p>Moderate to low quality evidence showed neither intravenous magnesium and oral magnesium therapy has an effect on reducing painful crisis, length of hospital stay and changing quality of life in treating sickle cell disease. Therefore, no definitive conclusions can be made regarding its clinical benefit. Further randomized controlled studies, perhaps multicentre, are necessary to establish whether intravenous and oral magnesium therapies have any effect on improving the health of people with sickle cell disease. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011358-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011358-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011358-abs-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011358-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011358-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011358-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011358-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011358-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011358-abs-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011358-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011358-abs-0005" lang="en"> <h3>Magnesium for treating sickle cell disease</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence of the effect of intravenous (given into a vein) magnesium and oral (taken by mouth) magnesium on the frequency of painful crises (sickle cell crises with severe pain due to blockages of the blood supply to bones, joints, lungs, liver, spleen, kidney, eye or central nervous system), length of hospital stay and quality of life in people with different types of sickle cell disease. </p> <p><b>Background</b> </p> <p>Sickle cell disease is a relatively common inherited blood disease. Its symptoms include the rapid onset of painful crises, which can lead to increased rates of hospital admission. The likely cause is that deformed sickle‐shaped red blood cells put stress on blood vessels which blocks them and leads to vaso‐occlusive crises. Vascular function is impaired in people with sickle cell disease. It is known that magnesium can widen blood vessels and, when regularly administered, it improves the amount of liquid in red blood cells and can help stop their shape deforming. Intravenous magnesium can cause mild to moderate side effects after administration e.g. nausea, vomiting, feeling of warmth, low blood pressure, etc.; and oral magnesium supplementation can cause mild side effects e.g. diarrhoea and abdominal cramps. We wanted to find out whether short‐term intravenous magnesium and long‐term oral magnesium is better than a placebo (dummy treatment with no magnesium) or no magnesium treatment, for reducing painful crises, shortening the length of stay in hospital and for improving quality of life. We were also interested in side effects of treatment with magnesium and some blood tests. This is an updated version of the review. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 03 February 2019.</p> <p><b>Study characteristics</b> </p> <p>The review included five studies with a total of 386 people with sickle cell disease aged between four and 53 years<i>.</i> Two studies (306 people) compared intravenous magnesium to a placebo (in this case saline (salty water)) in people admitted to hospital as an emergency because of pain and lasted until they were discharged (less than four weeks). Two of the three longer‐term studies compared oral magnesium pidolate with placebo and the third study compared hydroxyurea and magnesium pidolate to each other and to placebo but we have only included the results of the comparison of magnesium pidolate to placebo). </p> <p><b>Key results</b> </p> <p>Not all the studies reported on our outcomes and we could not analyse data from most of the studies. We did find that in the people admitted to hospital as emergency cases, intravenous magnesium did not reduce pain levels, could not shorten the length of time spent in hospital and did not improve their quality of life compared to placebo. However, more people given magnesium experienced warmth where the needle was inserted than those people who were given placebo. </p> <p>Oral magnesium pidolate, given over a longer period, did not reduce the severity of painful episodes and had no measurable effect on properties of sickled red cells (e.g. magnesium levels in the blood). Oral magnesium appeared to be safe and well‐tolerated with only mild side effects (diarrhoea and headache). Further research is needed to compare the short‐term and long‐term benefits of magnesium treatment and its side effects. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of evidence for intravenous magnesium and oral magnesium in treating sickle cell disease was moderate for pain when using short‐term intravenous magnesium and for levels of magnesium in the blood when taking longer‐term oral magnesium supplements. The quality of evidence was low for all other outcomes we measured. All of the included studies of oral or intravenous magnesium for treating sickle cell disease had some aspects that could undermine the reliability of their results. Therefore, we have some uncertainty of these findings and further research may provide evidence that could change our conclusions. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011358-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011358-sec-0108"></div> <h3 class="title" id="CD011358-sec-0109">Implications for practice</h3> <section id="CD011358-sec-0109"> <p>In this review, there is a lack of promising effects from either of the included parallel randomized controlled trials (RCTs) using intravenous magnesium (Mg) to treat people with sickle cell disease (SCD) admitted to hospital for a painful crisis (where pain started 24 hours before arrival at hospital) in reducing the painful crisis at hospital and improving health‐related quality of life (HRQoL) after discharge from hospital. </p> <p>There is also a lack of promising evidence from any RCT, either of parallel or cross‐over design, to support the use of oral Mg to treat people with SCD (with at least one vaso‐occlusive crisis in previous 12 months) in reducing the frequency of painful crises, reducing red cell dehydration by changing haematological and biochemical parameters and improving HRQoL. One oral Mg study was terminated early because of slow enrolment, but narrative results showed that no significant toxicity was observed in the Mg treatment arm. </p> <p>Our findings are supported by low quality evidence for intravenous Mg and low quality evidence for oral Mg. We are therefore unable to recommend that intravenous Mg sulphate or oral Mg pidolate are used to treat children or adults who are experiencing painful episodes or those with stable disease. </p> </section> <h3 class="title" id="CD011358-sec-0110">Implications for research</h3> <section id="CD011358-sec-0110"> <p>Neither intravenous Mg sulphate or oral Mg pidolate appear to be effective in treating painful crises in people with SCD. However, these conclusions are based on limited data and information from two studies of intravenous Mg sulphate and three studies of oral Mg pidolate, all with a small number of participants. Due to the limited current evidence, further RCTs may be warranted to determine whether intravenous Mg sulphate can reduce the length of hospital stay and improve the quality of life in people with SCD; and whether oral Mg can improve painful episodes and reduce red cell dehydration in people with SCD. Furthermore, data to justify proposing oral Mg pidolate as a potential therapeutic strategy for preventing erythrocyte dehydration in haemoglobin S disease is needed. Such studies must be sufficiently well‐designed and large enough to allow important differences to be detected. Since no definitive conclusions can be made about the clinical efficacy of Mg therapy, future research must consider further health‐related outcomes (including reporting on reducing sickle cell painful crises), as well as improving long‐term HRQoL outcomes. In addition, studies may address specific considerations including timing and safety of commencement of intravenous Mg sulphate and oral Mg pidolate as well as dosage for therapeutic benefits in management guidelines. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011358-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011358-sec-0029"></div> <div class="table" id="CD011358-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intravenous magnesium sulphate versus placebo for treating sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous magnesium sulphate versus placebo for treating sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : people with sickle cell disease<br/> <b>Settings</b> : emergency department (Toronto, Canada); children's hospital (USA)<br/> <b>Intervention</b>: intravenous magnesium sulphate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intravenous magnesium sulphate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in frequency of vaso‐occlusive painful crises</b> </p> <p><b>(as measured by pain diary of days with significant pain)</b> </p> <p>Follow up: Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain score in placebo group was <b>5.3</b>. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain score in the intervention group was <b>0.10 higher</b> (0.82 lower to 1.02 higher) than in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the mean pain score between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HRQoL score (Child‐reported PedsQL generic scale) at 1 week follow up</b> </p> <p>Follow up: 7‐10 days and 3 months after discharge from hospital</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HRQoL score (child‐reported HRQoL) in the intervention group was<br/> <b>2.3 lower</b> (7.21 lower to 2.61 higher) than in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the mean HRQoL score between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HRQoL score (Child‐reported PedsQL multidimensional fatigue scale) at 1 week follow up</b> </p> <p>Follow up: 7‐10 days and 3 months after discharge from hospital</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HRQoL score (child‐reported HRQoL) in the intervention group was <b>1.4 lower</b> (13.44 lower to 10.64 higher) than in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the mean HRQoL score between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HRQoL score (Child‐reported PedsQL sickle cell disease module) at 1 week follow up</b> </p> <p>Follow up: 7‐10 days and 3 months after discharge from hospital</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HRQoL score (child‐reported HRQoL) in the intervention group was 3.5<b>lower</b> (14.95 lower to 7.95 higher) than in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the mean HRQoL score between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay (hours)</b> </p> <p>Follow up: Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay in the control group was <b>117.9 hours.</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay in the intervention group was <b>14.7 higher</b> (20.51 lower to 49.91 higher) than in the placebo group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the mean length of hospital stay between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> hypotension </p> <p>Follow up: Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5</b> out of 151 participants. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2</b> out of 155 participants. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.57</b> <br/> (0.50 to 13.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in hypotension between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> warmth at infusion site </p> <p>Follow up: 7‐10 days and 3 months after discharge from hospital</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2</b> out of 102 participants. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26</b> out of 100 participants. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 13.26</b> <br/> (3.23 to 54.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was significant difference in warmth at the infusion site between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>HRQoL</b> : health‐related quality of life; <b>NA</b> : not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded due to serious limitation of risk of bias: the study lacked blinding of outcome assessment and the targeted sample size expected from protocol was not achieved.<br/> <sup>2</sup> Evidence downgraded to imprecision: wide 95% CIs of the effects of outcomes of the intervention.<br/> <sup>3</sup> Serious risk of bias: method of blinding of outcome assessment was not clearly described. Downgraded by one level from high.<br/> <sup>4</sup> The results from the study were presented as either median or mean difference so an estimate of risk within the control group is not available. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011358-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral magnesium pidolate versus placebo/no intervention for treating sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral magnesium versus placebo for treating sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : people with sickle cell disease<br/> <b>Settings</b> : outpatient (Europe)<br/> <b>Intervention</b>: oral magnesium pidolate </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo/no intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Magnesium</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in frequency of vaso‐occlusive painful crises</b> </p> <p><b>(as measured by pain diary days with significant pain)</b> </p> <p>Follow up: Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of painful days in the intervention group was <b>1.9 higher</b> (1.05 lower to 4.85 higher) than in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over randomized controlled study.</p> <p>There was no significant difference in the mean number of painful days between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Length of hospital stay</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in dense red cells in sickle cell disease</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effects of K‐Cl cotransport red cell K+ and Mg2+ content (RBC magnesium) mM/kg Hb</b> </p> <p>Follow up: Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean RBC magnesium in the intervention group was <b>0.46 higher</b> (0.29 lower to 1.21 higher) than in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over randomized controlled study.</p> <p>There was no significant difference in mean RBC magnesium between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events:</b> diarrhoea and headache </p> <p>Follow up: every 2 weeks then every 4 weeks.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 events that were considered probably related to drug (or placebo).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over randomized control study (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> <p>This study reported adverse events as total for both intervention and placebo period.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events:</b> including serious adverse events, vaso‐occlusive crisis, gastrointestinal disorder, headache or migraine, upper respiratory tract infection, rash </p> <p>Follow up: 26.3 patient years of follow up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>293 adverse events while receiving study drugs.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase II multi‐centre double‐blinded trial, factorial design (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). </p> <p>This study reported adverse events for four treatment arms. No differences were observed across the four treatment groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>K‐Cl</b> : potassium chloride; <b>NA</b> : not applicable; <b>RBC</b> : red blood cell; <b>RR:</b> Risk Ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Evidence downgraded to imprecision: wide 95% CIs of the effects of outcomes of the intervention.<br/> <sup>2</sup>Evidence downgraded due to reporting bias: the study protocol was not available.<br/> <sup>3</sup>The results from the study were presented as mean difference so an estimate of risk within the control group is not available.<br/> <sup>4</sup>Evidence downgraded due to unclear risk of selection bias (random sequence generation and allocation concealment) and reporting bias.<br/> <sup>5</sup>High risk of attrition bias: incomplete outcome data. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011358-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011358-sec-0030"></div> <section id="CD011358-sec-0031"> <h3 class="title" id="CD011358-sec-0031">Description of the condition</h3> <p>Sickle cell disease (SCD) is a hereditary red cell disorder found in populations across the world (<a href="./references#CD011358-bbs2-0096" title="WeatherallDJ , CleggJB . Inherited haemoglobin disorders: an increasing global health problem. Bulletin of the World Health Organization2001;79(8):704‐12. ">Weatherall 2001</a>). It is caused by a single point mutation in codon 6 of the human beta‐globin (β‐globin) gene that results in the substitution of valine for glutamic acid and the synthesis of pathological haemoglobin S (HbS). People with SCD can be homozygous for the pathological haemoglobin S(SS) or heterozygous with co‐inherited other haemoglobin disorders such as HbC (SC) or β‐thalassaemia (Sβ) (<a href="./references#CD011358-bbs2-0069" title="MehtaAB , HoffbrandAV . Chapter 17: Hemolytic anemias V. Inherited defects of hemoglobin— sickle cell disease. Hematology at a Glance. 1st Edition. Malden, Massachusetts: Blackwell Publishing, 2000:50. ">Mehta 2000</a>). The worldwide distribution of SCD has dramatically changed in recent decades due to the survival of people with SCD in endemic areas, such as sub‐Saharan countries, and the migration of populations from endemic areas to some western countries (<a href="./references#CD011358-bbs2-0070" title="ModellB , DarlisonM . Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ2008;86(6):480‐7. ">Modell 2008</a>; <a href="./references#CD011358-bbs2-0096" title="WeatherallDJ , CleggJB . Inherited haemoglobin disorders: an increasing global health problem. Bulletin of the World Health Organization2001;79(8):704‐12. ">Weatherall 2001</a>). The condition is characterized by decreased life expectancy targeting both paediatric and adult populations (<a href="./references#CD011358-bbs2-0047" title="HamidehD1 , AlvarezO . Sickle cell disease related mortality in the United States (1999‐2009). Pediatric Blood and Cancer2013;60(9):1482‐6. [DOI: 10.1002/pbc.24557] ">Hamideh 2013</a>; <a href="./references#CD011358-bbs2-0076" title="PlattOS , BrambillaDJ , RosseWF , MilnerPF , CastroO , SteinbergMH , et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine1994;330(23):1639‐44. ">Platt 1994</a>). Several years ago, the mean survival rate was 14.3 years for children with SCD (<a href="./references#CD011358-bbs2-0041" title="DiggsLM . Anatomic lesions in sickle cell disease. In: AbramsonH , BertlesJF , WethersDL editor(s). Sickle Cell Disease: Diagnosis, Management, Education and Research. St Louis: Mosby, 1973:189‐229. [ISBN‐10: 0801600375 ] ">Diggs 1973</a>), but this increased up to 20 years of age in children and adolescents as reported in a co‐operative study of SCD (<a href="./references#CD011358-bbs2-0063" title="LeikinSL , GallagherD , KinneyTR , SloaneD , KlugP , RidaW . Mortality in children and adolescents with sickle cell disease. Pediatrics1989;84(3):500‐8. ">Leikin 1989</a>). In adults with SCD life expectancy is 48 years for females and 42 years for males (<a href="./references#CD011358-bbs2-0076" title="PlattOS , BrambillaDJ , RosseWF , MilnerPF , CastroO , SteinbergMH , et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine1994;330(23):1639‐44. ">Platt 1994</a>). Mortality rates are low in children with SCD in developed countries (0.5 to 1.0 per 100,000 population) and high in some selected developing countries (15.5 per 1000 children) (<a href="./references#CD011358-bbs2-0079" title="RahimyMC , GangboA , AhouignanG , AlihonouE . Newborn screening for sickle cell disease in the Republic of Benin. Journal of Clinical Pathology2009;62(1):46‐8. ">Rahimy 2009</a>). </p> <p>In SCD, pathophysiological studies have shown that the dense, dehydrated red cells play a central role in acute and chronic clinical manifestations of SCD, in which production of sickle‐shaped red blood cells in capillaries and small vessels leads to obstruction of the microcirculation by sickled red blood cells, causing ischemias (<a href="./references#CD011358-bbs2-0016" title="BelcherJD , ChenC , NguyenJ , MilbauerL , AbdullaF , AlayashAI , et al. Heme triggers TLR4 signalling leading to endothelial cell activation and vaso‐occlusion in murine sickle cell disease. Blood2014;123(3):377‐90. [DOI: 10.1182/blood‐2013‐04‐495887] ">Belcher 2014</a>; <a href="./references#CD011358-bbs2-0039" title="DeFranceschiL , CappelliniMD , OlivieriO . Thrombosis and sickle cell disease. Seminars in Thrombosis and Hemostasis2011;37(3):226‐36. [DOI: 10.1055/s‐0031‐1273087] ">De Franceschi 2011</a>; <a href="./references#CD011358-bbs2-0048" title='HebbelRP . Reconstructing sickle cell disease: a data‐based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence‐based medicine. American Journal of Hematology2011;86(2):123‐54. [DOI: 10.1002/ajh.21952] '>Hebbel 2011</a>; <a href="./references#CD011358-bbs2-0089" title="SoloveyAA , SoloveyAN , HarknessJ , HebbelRP . Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood2001;97(7):1937‐41. ">Solovey 2001</a>; <a href="./references#CD011358-bbs2-0094" title="VinchiF , DeFranceschiL , GhigoA , TownesT , CiminoJ , SilengoL , et al. Hemopexin therapy improves cardiovascular function by preventing heme‐induced endothelial toxicity in mouse models of hemolytic diseases. Circulation2013;127(12):1317‐29. [DOI: 10.1161/CIRCULATIONAHA.112.130179] ">Vinchi 2013</a>). However, the persistent membrane damage with loss of deformability and changes in cell morphology (HbS polymerization) also favours the generation of distorted rigid cells and further contributes to vaso‐occlusive events and cell destruction in the peripheral circulation (<a href="./references#CD011358-bbs2-0039" title="DeFranceschiL , CappelliniMD , OlivieriO . Thrombosis and sickle cell disease. Seminars in Thrombosis and Hemostasis2011;37(3):226‐36. [DOI: 10.1055/s‐0031‐1273087] ">De Franceschi 2011</a>; <a href="./references#CD011358-bbs2-0059" title="KuypersFA , YuanJ , LewisRA , SnyderLM , KieferCR , BunyaratvejA , et al. Membrane phospholipid asymmetry in human Thalassemia. Blood1998;91(8):3044‐51. ">Kuypers 1998</a>). Studies in both mouse models and humans with SCD have shown that vaso‐occlusive crises (VOCs) result from a complex (and still only partially known) scenario, which also involves neutrophils, natural killer T‐cells (NKT cells) (<a href="./references#CD011358-bbs2-0039" title="DeFranceschiL , CappelliniMD , OlivieriO . Thrombosis and sickle cell disease. Seminars in Thrombosis and Hemostasis2011;37(3):226‐36. [DOI: 10.1055/s‐0031‐1273087] ">De Franceschi 2011</a>; <a href="./references#CD011358-bbs2-0043" title="FieldJJ , LinG , OkamMM , MajerusE , KeeferJ , OnyekwereO , et al. Sickle cell vaso‐occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood2013;121(17):3329‐34. [DOI: 10.1182/blood‐2012‐11‐465963] ">Field 2013</a>) and platelets (<a href="./references#CD011358-bbs2-0014" title="AtagaKI , OrringerEP . Hypercoagulability in sickle cell disease: a curious paradox. American Journal of Medicine2003;115(9):721‐8. ">Ataga 2003</a>; <a href="./references#CD011358-bbs2-0057" title="KlingsES , FarberHW . Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. Respiratory Research2001; Vol. 2, issue 5:280‐5. ">Klings 2001</a>; <a href="./references#CD011358-bbs2-0071" title="Okpala , I . The intriguing contribution of white blood cells to sickle cell disease – a red cell disorder. Blood Reviews2004;18(1):65‐73. ">Okpala 2004</a>), as well as soluble factors such as cytokines or the coagulation system (<a href="./references#CD011358-bbs2-0039" title="DeFranceschiL , CappelliniMD , OlivieriO . Thrombosis and sickle cell disease. Seminars in Thrombosis and Hemostasis2011;37(3):226‐36. [DOI: 10.1055/s‐0031‐1273087] ">De Franceschi 2011</a>; <a href="./references#CD011358-bbs2-0086" title="SabaaN , deFranceschiL , BonninP , CastierY , MalpeliG , DebbabiH , et al. Endothelin receptor antagonism prevents hypoxia‐induced mortality and morbidity in a mouse model of sickle‐cell disease. Journal of Clinical Investigation2008;118(5):1924‐33. [DOI: 10.1172/JCI33308] ">Sabaa 2008</a>). In SCD, recurrent VOCs promote tissue damage, characterized by chronic inflammation and ischaemia‐reperfusion cellular injury (where ischaemia means a lack of oxygen) that leads to acute and chronic multi‐organ dysfunction (<a href="./references#CD011358-bbs2-0081" title="ReiterCD , GladwinMT . An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Current Opinion in Hematology2003;10(2):99‐107. ">Reiter 2003</a>). In young children, the main clinical manifestations of VOCs are dactylitis, osteomyelitis, osteonecrosis, splenic infarct, splenic sequestration, acute chest syndrome, stroke, papillary necrosis leading to kidney failure (<a href="./references#CD011358-bbs2-0099" title="YasterM , Kost‐ByerlyS , MaxwellLG . The management of pain in sickle cell disease. Pediatric Clinics of North America2000;47(3):699‐710. ">Yaster 2000</a>). In young adults with SCD the most frequent causes of hospitalizations are pain crisis, pneumonia, sepsis, acute chest syndrome and heart failure (<a href="./references#CD011358-bbs2-0022" title="BrousseauDC , OwensPL , MossoAL , PanepintoJA , SteinerCA . Acute care utilization and rehospitalization for sickle cell disease. JAMA2010;303(13):1288‐94. [DOI: 10.1001/jama.2010.378] ">Brousseau 2010</a>; <a href="./references#CD011358-bbs2-0030" title="CarrollCP , HaywoodCJr , FaganP , LanzkronS . The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization. American Journal of Hematology2009;84(10):666‐70. [DOI: 10.1002/ajh.21515] ">Caroll 2009</a>; <a href="./references#CD011358-bbs2-0077" title="PlattOS . The acute chest syndrome of sickle cell disease. New England Journal of Medicine2000;342(25):1904‐7. ">Platt 2000</a>). </p> <p>Recent evidence on the presence of circulating free heme and haemoglobin, related to the saturation of the physiological binding system, such as haptoglobin and haemopexin (<a href="./references#CD011358-bbs2-0031" title="DeCaterinaR , LibbyP , PengHB , ThannickalVJ , RajavashisthTB , GimbroneMAJr , et al. Nitric oxide decreases cytokine‐induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecule and pro inflammatory cytokines. Journal of Clinical Investigation1995;96(1):60‐8. ">De Caterina 1995</a>; <a href="./references#CD011358-bbs2-0061" title="LanePA . Sickle cell disease. Pediatric Clinics of North America1996;43(3):639‐64. ">Lane 1996</a>; <a href="./references#CD011358-bbs2-0094" title="VinchiF , DeFranceschiL , GhigoA , TownesT , CiminoJ , SilengoL , et al. Hemopexin therapy improves cardiovascular function by preventing heme‐induced endothelial toxicity in mouse models of hemolytic diseases. Circulation2013;127(12):1317‐29. [DOI: 10.1161/CIRCULATIONAHA.112.130179] ">Vinchi 2013</a>) has opened an interesting prospective on the intravascular pro‐oxidant environment and the local reduction of nitric oxide, which avidly binds free Hb promoting regional relative nitric oxide deficiency (<a href="./references#CD011358-bbs2-0037" title="deFranceschiL , BaronA , ScarpaA , AdrieC , JaninA , BarbiS , et al. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease‐specific lung injury induced by hypoxia/reoxygenation. Blood2003;102(3):1087‐96. ">De Franceschi 2003</a>; <a href="./references#CD011358-bbs2-0056" title="KatoGJ , GladwinMT . Evolution of novel small‐molecule therapeutics targeting sickle cell vasculopathy. JAMA2008;300(22):2638‐46. [DOI: 10.1001/jama.2008.598] ">Kato 2008</a>; <a href="./references#CD011358-bbs2-0080" title="ReesDC , WilliamsTN , GladwinMT . Sickle‐cell disease. Lancet2010;376(9757):2018‐31. [DOI: 10.1016/S0140‐6736(10)61029‐X] ">Rees 2010</a>; <a href="./references#CD011358-bbs2-0088" title="SicilianoA , MalpeliG , PlattOS , LebouefC , JaninA , ScarpaA , et al. Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy. Haematologica2011;96(1):24‐32. [DOI: 10.3324/haematol.2010.028506] ">Siciliano 2011</a>). Thus, the two main clinical manifestations of SCD are acute VOCs and chronic haemolytic anaemia. </p> <p>The clinical manifestations of SCD are related to the peculiar biochemical properties of HbS, which polymerises when deoxygenated. Sickling of red blood cells has been shown to be exponentially related to the haemoglobin concentration. This demonstrates a crucial role of HbS concentration in sickling. Cyclic polymerization‐depolymerization of HbS is paralleled by the abnormal activation of red cell membrane cation systems resulting in a reduction of cell ion and water content (cell dehydration), increased red cell density and further acceleration of HbS polymerizations (<a href="./references#CD011358-bbs2-0025" title="BrugnaraC , deFranceschiL , AlperSL . Inhibition of Ca(2+)‐dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. Journal of Clinical Investigation1993;92(1):520‐6. ">Brugnara 1993a</a>; <a href="./references#CD011358-bbs2-0032" title="DeFranceschiL , SaadaneN , TrudelM , AlperSL , BrugnaraC , BeuzardY . Treatment with oral clotrimazole blocks Ca(2+)‐activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. Journal of Clinical Investigation1994;93(4):1670‐6. ">De Franceschi 1994</a>; <a href="./references#CD011358-bbs2-0068" title="McNaughton‐SmithGA , BurnsJF , StockerJW , RigdonGC , CreechC , ArringtonS , et al. Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. Journal of Medicinal Chemistry2008;51(4):976‐82. [DOI: 10.1021/jm070663s] ">McNaughton‐Smith 2008</a>; <a href="./references#CD011358-bbs2-0091" title="StockerJW , DeFranceschiL , McNaughton‐SmithGA , CorrocherR , BeuzardY , BrugnaraC . ICA‐17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood2003;101(6):2412‐8. ">Stocker 2003</a>). Dense, dehydrated erythrocytes are likely to undergo instant polymerizations in conditions of mild hypoxia due to their high HbS concentration, and HbS polymers may be formed under normal oxygen pressure. </p> <p>Analysis of membrane physiology of sickled red cells have shown abnormalities in different specialized membrane‐embedded transporters that carry cations, anions and water across the erythrocyte membrane. In the last two decades, studies on the nature and properties of the pathways mediating potassium (K<sup>+</sup>) loss in sickle cell erythrocytes have identified three major membrane systems; the Ca<sup>2+</sup>‐activated K<sup>+</sup> channel, known as the Gardos channel (<a href="./references#CD011358-bbs2-0025" title="BrugnaraC , deFranceschiL , AlperSL . Inhibition of Ca(2+)‐dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. Journal of Clinical Investigation1993;92(1):520‐6. ">Brugnara 1993a</a>; <a href="./references#CD011358-bbs2-0032" title="DeFranceschiL , SaadaneN , TrudelM , AlperSL , BrugnaraC , BeuzardY . Treatment with oral clotrimazole blocks Ca(2+)‐activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. Journal of Clinical Investigation1994;93(4):1670‐6. ">De Franceschi 1994</a>; <a href="./references#CD011358-bbs2-0034" title="DeFranceschiL , BeuzardY , JouaultH , BrugnaraC . Modulation of erythrocyte potassium chloride cotransport, potassium content, and density by dietary magnesium intake in transgenic SAD mouse. Blood1996;88(7):2738‐44. ">De Franceschi 1996</a>; <a href="./references#CD011358-bbs2-0093" title="VandorpeDH , ShmuklerBE , JiangL , LimB , MaylieJ , AdelmanJP , et al. cDNA cloning and functional characterization of the mouse Ca2+‐gated K+ channel, mIK1. Roles in regulatory volume decrease and erythroid differentiation. Journal of Biological Chemistry1998;273(34):21542‐53. ">Vandorpe 1998</a>), operating in parallel with the conductive Cl<sup>‐</sup> pathway (<a href="./references#CD011358-bbs2-0017" title="BennekouP , deFranceschiL , PedersenO , LianL , AsakuraT , EvansG , et al. Treatment with NS3623, a novel Cl‐conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease. Blood2001;97(5):1451‐7. ">Bennekou 2001</a>) and the electroneutral potassium chloride (K‐Cl) co‐transport (<a href="./references#CD011358-bbs2-0023" title="BrugnaraC , BunnHF , TostesonDC . Regulation of erythrocyte cation and water content in sickle cell anaemia. Science1986;232(4748):388‐90. ">Brugnara 1986</a>; <a href="./references#CD011358-bbs2-0092" title="SuW , ShmuklerBE , ChernovaMN , Stuart‐TilleyAK , deFranceschiL , BrugnaraC , et al. Mouse K‐Cl cotransporter KCC1: cloning, mapping, pathological expression, and functional regulation. American Journal of Physiology1999;277(5 Pt 1):C899‐912. ">Su 1999</a>). A role for the energy driven Na‐K pump system has also been identified as contributing to sickled red cell abnormalities (<a href="./references#CD011358-bbs2-0055" title="JoinerCH , MorrisCL , CooperES . Deoxygenation‐induced cation fluxes in sickle cells. III. Cation selectivity and response to pH and membrane potential. American Journal of Physiology1993;264(3 Pt 1):C734—44. ">Joiner 1993</a>). Specific inhibitors for either the Gardos channel or the conductive Cl<sup>‐</sup> pathway have been developed for SCD, but no specific pharmacological blockers are available for the K‐Cl co‐transport (<a href="./references#CD011358-bbs2-0026" title="BrugnaraC , deFranceschiL . Effect of cell age and phenylhydrazine on the cation transport properties of rabbit erythrocytes. Journal of Cellular Physiology1993;154(2):271‐80. ">Brugnara 1993b</a>; <a href="./references#CD011358-bbs2-0033" title="DeFranceschiL , BeuzardY , BrugnaraC . Sulfhydryl oxidation and activation of red cell K(+)‐Cl‐ cotransport in the transgenic SAD mouse. American Journal of Physiology1995;269(4 Pt 1):C899‐906. ">De Franceschi 1995</a>; <a href="./references#CD011358-bbs2-0034" title="DeFranceschiL , BeuzardY , JouaultH , BrugnaraC . Modulation of erythrocyte potassium chloride cotransport, potassium content, and density by dietary magnesium intake in transgenic SAD mouse. Blood1996;88(7):2738‐44. ">De Franceschi 1996</a>), whose activity is regulated by magnesium (Mg) concentration and through a balance between kinase(s) and phosphatase(s) (<a href="./references#CD011358-bbs2-0007" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , AlperS , et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. Journal of Clinical Investigation1997;100(7):1847‐52. ">De Franceschi 1997</a>). </p> </section> <section id="CD011358-sec-0032"> <h3 class="title" id="CD011358-sec-0032">Description of the intervention</h3> <p>Studies in recent decades have highlighted the high bio‐complexity of SCD, which requires the development of new therapeutic strategies. These strategies should be oriented towards multiple targets in order to affect the range of clinical manifestations of SCD. </p> <p>Magnesium is needed for more than 300 biochemical reactions in the body to maintain various cellular functions in different organs. A normal adult human body contains approximately 1000 mmol of Mg (22 g to 26 g), most of which is present in bone (up to 60%) and the remainder is present in skeletal muscle, soft tissues, extracellular fluid and intracellular fluid. Total serum Mg ranges from 0.70 to 1.10 mmol/L (<a href="./references#CD011358-bbs2-0087" title="SarisNE , MervaalaE , KarppanenH , KhawajaJA , LewenstamA . Magnesium: an update on physiological, clinical, and analytical aspects. Clinica Chimica Acta2000;294(1‐2):1‐26. ">Saris 2000</a>). Generally, Mg is absorbed in the small intestine and excreted through kidneys (<a href="./references#CD011358-bbs2-0085" title="RudeRK . Magnesium deficiency: A cause of heterogeneous disease in humans. Journal of Bone and Mineral Research1998;13(4):749‐58. ">Rude 1998</a>). The mean (standard deviation (SD)) daily dietary intake of Mg in a UK study was reported as 418 (120) mg for men and 343 (94) mg for women (<a href="./references#CD011358-bbs2-0021" title="BrittonJ , PavordI , RichardsK , WisniewskiA , KnoxA , LewisS , et al. Dietary magnesium, lung function, wheezing, and airway hyperreactivity in a random adult population sample. Lancet1994;344(8919):357‐62. ">Britton 1994</a>). The recommended daily allowance (RDA) in adults is 4.5 mg/kg/day. The requirement is higher in pregnancy or during lactation and debilitating illness (<a href="./references#CD011358-bbs2-0087" title="SarisNE , MervaalaE , KarppanenH , KhawajaJA , LewenstamA . Magnesium: an update on physiological, clinical, and analytical aspects. Clinica Chimica Acta2000;294(1‐2):1‐26. ">Saris 2000</a>). Supplementation with Mg may be indicated in a number of specific health conditions such as cardiovascular diseases, neurological disorders, bronchospasm, spinal cord injury or diabetes which are characterized by Mg cellular deficiency or a relative reduction in Mg absorption (<a href="./references#CD011358-bbs2-0060" title="LadefogedK , HessovI , JarnumS . Nutrition in short‐bowel syndrome. Scandinavian Journal of Gastroenterology. Supplement1996;216:122‐31. ">Ladefoged 1996</a>; <a href="./references#CD011358-bbs2-0095" title="VormannJ . Magnesium: nutrition and metabolism. Molecular Aspects of Medicine   2003;24(1‐3):27‐37. ">Vormann 2003</a>; <a href="./references#CD011358-bbs2-0097" title="WesterPO . Magnesium. American Journal of Clinical Nutrition1987;45(5 Suppl):1305‐12. ">Wester 1987</a>). </p> <p>Magnesium plays a key role in heart rhythm, immune system functions, bone metabolism, sugar metabolism and arterial blood pressure (<a href="./references#CD011358-bbs2-0075" title="PatelBM , RaghunathanS , PorwalU . Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus. European Journal of Pharmacology2014;728C:128‐34. [DOI: 10.1016/j.ejphar.2014.01.063] ">Patel 2014</a>; <a href="./references#CD011358-bbs2-0045" title="Galli‐TsinopoulouA , MagganaI , KyrgiosI , MouzakiK , GrammatikopoulouMG , StylianouC , et al. Association between magnesium concentration and HbA1c in children and adolescents with type 1 diabetes mellitus. Journal of Diabetes2014;6(4):369‐77. [DOI: 10.1111/1753‐0407.12118] ">Galli‐Tsinopoulou 2014</a>; <a href="./references#CD011358-bbs2-0074" title="OrchardTS , LarsonJC , AlghothaniN , Bout‐TabakuS , CauleyJA , ChenZ , et al. Magnesium intake, bone mineral density, and fractures: results from the Women's Health Initiative Observational Study. American Journal of Clinical Nutrition 2014 Feb 05 [Epub ahead of print]. ">Orchard 2014</a>; <a href="./references#CD011358-bbs2-0087" title="SarisNE , MervaalaE , KarppanenH , KhawajaJA , LewenstamA . Magnesium: an update on physiological, clinical, and analytical aspects. Clinica Chimica Acta2000;294(1‐2):1‐26. ">Saris 2000</a>; <a href="./references#CD011358-bbs2-0097" title="WesterPO . Magnesium. American Journal of Clinical Nutrition1987;45(5 Suppl):1305‐12. ">Wester 1987</a>). Intracellular Mg is an important co‐factor for various enzymes, transporters, and nucleic acids that are essential for replication and energy metabolism (<a href="./references#CD011358-bbs2-0019" title="BringhurstFRDM , KraneSM , KronenbergHM . Harrison's Principles of Internal Medicine. 18th Edition. New York: McGraw‐Hill, 2012. ">Bringhurst 2012</a>). Magnesium also plays a crucial role in the modulation of endothelial inflammation, which may be beneficial in SCD, a pro‐inflammatory disease with increased circulating levels of inflammatory cytokines IL‐1b, IL‐6 and TNFa, and expression of endothelial VCAM‐1 (<a href="./references#CD011358-bbs2-0020" title="BrittainJE , PariseLV . Cytokines and plasma factors in sickle cell disease. Current Opinion in Hematology2007;14(5):438–43. ">Brittain 2007</a>; <a href="./references#CD011358-bbs2-0064" title="MaierJA , Malpuech‐BrugereC , ZimowskaW , et al. Low magnesium promotes endothelial cell dysfunction: Implications for atherosclerosis, inflammation and thrombosis. Biochimica Biophysica Acta2004;1689:13–21. ">Maier 2004</a>; <a href="./references#CD011358-bbs2-0065" title="MakisAC , HatzimichaelEC , BourantasKL . The role of cytokines in sickle cell disease. Annals of Hematology2000;79(8):407–13. ">Makis 2000</a>). This modulation may be beneficial with increased circulating levels of cytokines in a pro‐inflammatory SCD disease with painful crisis. </p> <p>Intravenous Mg reduces VOCs through two mechanisms: a direct inhibition of calcium in the vascular smooth‐muscle wall; and an endothelial‐dependent release of nitric oxide (<a href="./references#CD011358-bbs2-0066" title="MathewR , AlturaBM . Magnesium and the lungs. Magnesium1988;7:173–87. ">Mathew 1988</a>; <a href="./references#CD011358-bbs2-0098" title="YangZW , GebrewoldA , NowakowskiM , AlturaBT , AlturaBM . Mg2þ‐induced endothelium‐dependent relaxation of blood vessels and blood pressure lowering: Role of NO. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology2000;278:R628‐R639. ">Yang 2000</a>). Moderate adverse effects of intravenous Mg sulphate administration are vomiting, nausea, a feeling of warmth, flushing, hypotension, bradycardia, somnolence, double vision, slurred speech and weakness, in particular when it is rapidly administered. These side effects usually occur when the total plasma magnesium level reaches 3.5 to 5 mmol/L (almost double the normal Mg plasma levels) (<a href="./references#CD011358-bbs2-0058" title="KnochelJP . Disorders of magnesium metabolism. Harrison's Principles of Internal Medicine. 14th Edition. New York: McGraw Hill, 1997. [ISBN: 0070202915] ">Knochel 1997</a>; <a href="./references#CD011358-bbs2-0049" title="HermansC , LefebvreC , DevolgelaerJP , LambertM . Hypocalcaemia and chronic alcohol intoxication: transient hypoparathyroidism secondary to magnesium deficiency. Clinical Rheumatology1996;15(2):193‐6. ">Hermans 1996</a>). The most severe effects of severe hypermagnesaemia (defined as Mg levels of 5 to 10 mmol/L) are neurological (e.g. fixed and dilated pupils, muscular paralysis, hyporeflexia, neuromuscular block with respiratory failure) (<a href="./references#CD011358-bbs2-0084" title="RizzoMA , FisherM , LockJP . Hypermagnesemic pseudocoma. Archives Internal Medicine1993;153(9):1130‐2. ">Rizzo 1993</a>) and cardiovascular (e.g. junctional or sinus bradycardia, sinoatrial block, atrioventricular block, and asystole) (<a href="./references#CD011358-bbs2-0018" title="BernsAS , KollmeyerKR . Magnesium‐induced bradycardia. Annals of Internal Medicine1976;85(6):760‐1. ">Berns 1976</a>; <a href="./references#CD011358-bbs2-0058" title="KnochelJP . Disorders of magnesium metabolism. Harrison's Principles of Internal Medicine. 14th Edition. New York: McGraw Hill, 1997. [ISBN: 0070202915] ">Knochel 1997</a>; <a href="./references#CD011358-bbs2-0067" title="MauskopA , AlturaBM . Role of magnesium in the pathogenesis and treatment of migraines. Clinical Neuroscience1998;5(1):24‐7. ">Mauskop 1998</a>). </p> <p>Oral Mg is an important regulator of different ion transport and membrane systems, either directly in exchange systems such as the Na‐Mg exchange or the K‐Cl co‐transport (<a href="./references#CD011358-bbs2-0036" title="DeFranceschiL , Villa‐MoruzziE , FumagalliL , BrugnaraC , TurriniF , MottaR , et al. K‐Cl cotransport modulation by intracellular Mg in erythrocytes from mice bred for low and high Mg levels. American Journal of Physiology. Cell Physiology2001;281(4):C1385‐95. ">De Franceschi 2001</a>; <a href="./references#CD011358-bbs2-0038" title="DeFranceschiL , Villa‐MoruzziE , BiondaniA , SicilianoA , BrugnaraC , AlperSL , et al. Regulation of K‐Cl cotransport by protein phosphatase 1alpha in mouse erythrocytes. Pflugers Archiv : European Journal of Physiology2006;451(6):760‐8. ">De Franceschi 2006</a>; <a href="./references#CD011358-bbs2-0083" title="RiveraA , FerreiraA , BertoniD , RomeroJR , BrugnaraC . Abnormal regulation of Mg2+ transport via Na/Mg exchanger in sickle erythrocytes. Blood2005;105(1):382‐6. ">Rivera 2005</a>); or indirectly as an essential co‐factor for sodium‐stimulated phosphorylation of the sodium potassium adenosine triphosphate metabolism (ATP) (Na‐K ATPase) (<a href="./references#CD011358-bbs2-0044" title="FlatmanPW , LewVL . The magnesium dependence of sodium‐pump‐mediated sodium‐potassium and sodium‐sodium exchange in intact human red cells. Journal of Physiology1981;315:421‐46. ">Flatman 1981</a>). Oral Mg supplementation with different preparations such as Mg sulphate, Mg glutamate or Mg pidolate can cause some mild side effects such as diarrhoea and abdominal cramps (<a href="./references#CD011358-bbs2-0007" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , AlperS , et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. Journal of Clinical Investigation1997;100(7):1847‐52. ">De Franceschi 1997</a>). </p> </section> <section id="CD011358-sec-0033"> <h3 class="title" id="CD011358-sec-0033">How the intervention might work</h3> <p>Red blood cell dehydration in SCD is related to cyclic HbS polymerisation which is associated with reduced red cell Mg content. The reduced red cell Mg content is most likely related to abnormal red cell membrane permeability to double‐charged ions such as Mg and calcium (Ca) during deoxygenation events and to the abnormal activation of the Na‐Mg exchange (<a href="./references#CD011358-bbs2-0007" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , AlperS , et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. Journal of Clinical Investigation1997;100(7):1847‐52. ">De Franceschi 1997</a>; <a href="./references#CD011358-bbs2-0008" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , NeubergD , et al. Oral magnesium pidolate: effects of long‐term administration in patients with sickle cell disease. British Journal of Haematology2000;108(2):284‐9. ">De Franceschi 2000</a>; <a href="./references#CD011358-bbs2-0083" title="RiveraA , FerreiraA , BertoniD , RomeroJR , BrugnaraC . Abnormal regulation of Mg2+ transport via Na/Mg exchanger in sickle erythrocytes. Blood2005;105(1):382‐6. ">Rivera 2005</a>). The role of Mg content in erythrocytes for regulating K‐Cl co‐transport has been demonstrated in normal human controls and people with SCD (<a href="./references#CD011358-bbs2-0024" title="BrugnaraC , TostesonDC . Inhibition of K transport by divalent cations in sickle erythrocytes. Blood1987;70(6):1810–5. ">Brugnara 1987</a>; <a href="./references#CD011358-bbs2-0029" title="CanessaM , FabryME , NagelRL . Deoxygenation inhibits the volume‐stimulated, Cl‐dependent K1 efflux in SS and young AA cells: a cytosolic Mg11 modulation. Blood1987;70(6):1861–6. ">Canessa 1987</a>). Studies on the level of Mg content are variable; some studies showed normal circulating levels of Mg (<a href="./references#CD011358-bbs2-0012" title="AkenamiFO , Aken’OvaYA , OsifoBO . Serum zinc, copper and magnesium in sickle cell disease at Ibadan, southwestern Nigeria. African Journal of Medical Sciences1999;28(3‐4):137‐9. ">Akenami 1999</a>; <a href="./references#CD011358-bbs2-0072" title="OladipoOO ,  TemiyeEO ,  EzeakaVC ,  ObomanuP . Serum magnesium, phosphate and calcium in Nigerian children with sickle cell disease. West African Medical Journal2005;24(2):120–3. ">Oladipo 2005</a>), while others reported low levels (<a href="./references#CD011358-bbs2-0073" title="OlukogaAO , AdewoyeHO , ErasmusRT , AdedoyinMA . Erythrocyte and plasma magnesium in sickle‐cel anaemia. East African Medical Journal1990;67(5):348‐54. ">Olukoga 1990</a>; <a href="./references#CD011358-bbs2-0100" title="ZehtabchiS ,  SinertR ,  RinnertS ,  ChangB ,  HeinisC ,  AlturaRA , et al. Serum ionized magnesium levels and ionized calcium‐to‐magnesium ratios in adult patients with sickle cell anaemia. American Journal of Hematology2004;77(3):215‐22. ">Zehtabchi 2004</a>). However, plasma levels do not reflect the intracellular Mg content and the amount of free Mg, which is important in the context of cellular functions (<a href="./references#CD011358-bbs2-0036" title="DeFranceschiL , Villa‐MoruzziE , FumagalliL , BrugnaraC , TurriniF , MottaR , et al. K‐Cl cotransport modulation by intracellular Mg in erythrocytes from mice bred for low and high Mg levels. American Journal of Physiology. Cell Physiology2001;281(4):C1385‐95. ">De Franceschi 2001</a>; <a href="./references#CD011358-bbs2-0038" title="DeFranceschiL , Villa‐MoruzziE , BiondaniA , SicilianoA , BrugnaraC , AlperSL , et al. Regulation of K‐Cl cotransport by protein phosphatase 1alpha in mouse erythrocytes. Pflugers Archiv : European Journal of Physiology2006;451(6):760‐8. ">De Franceschi 2006</a>). </p> <p>In SCD, red cell dehydration is related to abnormally high red cell membrane permeability during deoxygenation and the loss of potassium through the activation of two important pathways: the Gardos channel (<a href="./references#CD011358-bbs2-0093" title="VandorpeDH , ShmuklerBE , JiangL , LimB , MaylieJ , AdelmanJP , et al. cDNA cloning and functional characterization of the mouse Ca2+‐gated K+ channel, mIK1. Roles in regulatory volume decrease and erythroid differentiation. Journal of Biological Chemistry1998;273(34):21542‐53. ">Vandorpe 1998</a>); and the K‐Cl co‐transporter (<a href="./references#CD011358-bbs2-0023" title="BrugnaraC , BunnHF , TostesonDC . Regulation of erythrocyte cation and water content in sickle cell anaemia. Science1986;232(4748):388‐90. ">Brugnara 1986</a>; <a href="./references#CD011358-bbs2-0027" title="BrugnaraC . Red cell dehydration in pathophysiology and treatment of sickle cell disease. Current Opinion in Hematology1995;2(2):132‐8. ">Brugnara 1995</a>). The activity of the K‐Cl co‐transport is affected by cell Mg content, oxidative stress and cyclic phosphorylation and dephosphorylation events (<a href="./references#CD011358-bbs2-0026" title="BrugnaraC , deFranceschiL . Effect of cell age and phenylhydrazine on the cation transport properties of rabbit erythrocytes. Journal of Cellular Physiology1993;154(2):271‐80. ">Brugnara 1993b</a>; <a href="./references#CD011358-bbs2-0033" title="DeFranceschiL , BeuzardY , BrugnaraC . Sulfhydryl oxidation and activation of red cell K(+)‐Cl‐ cotransport in the transgenic SAD mouse. American Journal of Physiology1995;269(4 Pt 1):C899‐906. ">De Franceschi 1995</a>; <a href="./references#CD011358-bbs2-0007" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , AlperS , et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. Journal of Clinical Investigation1997;100(7):1847‐52. ">De Franceschi 1997</a>; <a href="./references#CD011358-bbs2-0008" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , NeubergD , et al. Oral magnesium pidolate: effects of long‐term administration in patients with sickle cell disease. British Journal of Haematology2000;108(2):284‐9. ">De Franceschi 2000</a>); increased red cell Mg levels can inhibit the K‐Cl cotransport activity (<a href="./references#CD011358-bbs2-0026" title="BrugnaraC , deFranceschiL . Effect of cell age and phenylhydrazine on the cation transport properties of rabbit erythrocytes. Journal of Cellular Physiology1993;154(2):271‐80. ">Brugnara 1993b</a>; <a href="./references#CD011358-bbs2-0033" title="DeFranceschiL , BeuzardY , BrugnaraC . Sulfhydryl oxidation and activation of red cell K(+)‐Cl‐ cotransport in the transgenic SAD mouse. American Journal of Physiology1995;269(4 Pt 1):C899‐906. ">De Franceschi 1995</a>; <a href="./references#CD011358-bbs2-0007" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , AlperS , et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. Journal of Clinical Investigation1997;100(7):1847‐52. ">De Franceschi 1997</a>; <a href="./references#CD011358-bbs2-0008" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , NeubergD , et al. Oral magnesium pidolate: effects of long‐term administration in patients with sickle cell disease. British Journal of Haematology2000;108(2):284‐9. ">De Franceschi 2000</a>). Thus, changes in red cell Mg content in SCD can reduce the abnormal activation of K‐Cl co‐transport, preventing at least one of the components of sickle red cell dehydration (<a href="./references#CD011358-bbs2-0024" title="BrugnaraC , TostesonDC . Inhibition of K transport by divalent cations in sickle erythrocytes. Blood1987;70(6):1810–5. ">Brugnara 1987</a>; <a href="./references#CD011358-bbs2-0027" title="BrugnaraC . Red cell dehydration in pathophysiology and treatment of sickle cell disease. Current Opinion in Hematology1995;2(2):132‐8. ">Brugnara 1995</a>). </p> <p>Several uncontrolled studies have reported beneficial effects of the intravenous administration of Mg sulphate or the oral administration of Mg citrate in people with SCD (<a href="./references#CD011358-bbs2-0013" title="AnstallHB , HaywardGH , HuntsmanRG , WeitzmanD , LehmannH . The effect of magnesium on blood coagulation in human subjects. Lancet1959;1(7077):814‐5. ">Anstall 1959</a>; <a href="./references#CD011358-bbs2-0062" title="LehmannH . Treatment of sickle cell anaemia. British Medical Journal1963;1(5338):1158‐9. ">Lehmann 1963</a>). </p> <p>In one study, intravenous Mg sulphate was administered in children with SS type of SCD being treated for painful crises; it was observed that the length of hospital stay decreased (<a href="./references#CD011358-bbs2-0006" title="BrousseauDC , ScottJP , HilleryCA , PanepintoJA . The effect of magnesium on length of stay for pediatric sickle cell pain crisis. Academic Emergency Medicine2004;11(9):968‐71. ">Brousseau 2004</a>). As there were no previous studies of Mg supplementation in children in with SCD, the dosage of intravenous Mg sulphate was lower than the dose used for other conditions (40 mg/kg) (<a href="./references#CD011358-bbs2-0028" title="BuchananGR , DeBaunMR , QuinnCT , SteinbergMH . Sickle cell disease. American Society of Hematology Education Program2004;1:35‐47. ">Buchanan 2004</a>). In another study, intravenous Mg sulphate was administered in people with SS or HbS β‐thalassaemia experiencing sickle cell pain crisis. It was seen that treatment decreased the duration of the VOC and subsequently decreased in length of hospital stay (<a href="./references#CD011358-bbs2-0015" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for paediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomised controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. ">Badaki 2014</a>). </p> <p>It has been observed that oral Mg supplements, such as Mg pidolate, have significantly improved red cell hydration by reducing the number of dense sickle erythrocytes, absolute reticulocyte count and immature reticulocytes, while erythrocyte Mg and potassium content were significantly increased (<a href="./references#CD011358-bbs2-0007" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , AlperS , et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. Journal of Clinical Investigation1997;100(7):1847‐52. ">De Franceschi 1997</a>; <a href="./references#CD011358-bbs2-0008" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , NeubergD , et al. Oral magnesium pidolate: effects of long‐term administration in patients with sickle cell disease. British Journal of Haematology2000;108(2):284‐9. ">De Franceschi 2000</a>; <a href="./references#CD011358-bbs2-0100" title="ZehtabchiS ,  SinertR ,  RinnertS ,  ChangB ,  HeinisC ,  AlturaRA , et al. Serum ionized magnesium levels and ionized calcium‐to‐magnesium ratios in adult patients with sickle cell anaemia. American Journal of Hematology2004;77(3):215‐22. ">Zehtabchi 2004</a>). One study used oral Mg as a short‐term treatment (less than four weeks) at a dose of 0.6 morphine equivalent (meq)/kg/day (504 mg/day) (<a href="./references#CD011358-bbs2-0007" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , AlperS , et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. Journal of Clinical Investigation1997;100(7):1847‐52. ">De Franceschi 1997</a>) and another unblinded trial study used Mg pidolate in people with SCD homozygous for HbS (SS) as a long‐term treatment at a dose of 540 mg/day for six months (<a href="./references#CD011358-bbs2-0008" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , NeubergD , et al. Oral magnesium pidolate: effects of long‐term administration in patients with sickle cell disease. British Journal of Haematology2000;108(2):284‐9. ">De Franceschi 2000</a>). The later study found that there was significantly reduced number of painful days during the six‐month period. </p> </section> <section id="CD011358-sec-0034"> <h3 class="title" id="CD011358-sec-0034">Why it is important to do this review</h3> <p>This review aims to bring together evidence for the impact of intravenous Mg to reduce the pain and improve the quality of life in people with different SCD genotypes who are admitted to hospital for a painful crisis. It also aims to find out the effects of longer‐term oral Mg on the frequency of painful crises and on the quality of life of people who are in a steady state of SCD, in order to ameliorate red cell dehydration and hematological phenotype. This review hopes to establish the clinical value of a pharmaceutical approach. This is an updated version of the original review (<a href="./references#CD011358-bbs2-0101" title="ThanNN , SoeHHK , PalaniappanSK , AbasABL , DeFranceschiL . Magnesium for treating sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD011358.pub2] ">Than 2017</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011358-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011358-sec-0035"></div> <p>To evaluate the effects of intravenous Mg on the length of hospital stay and quality of life in children and adults with SCD. </p> <p>To determine the effects of oral Mg therapy on the frequency of painful crises and the quality of life in children and adults with SCD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011358-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011358-sec-0036"></div> <section id="CD011358-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011358-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomized controlled studies and quasi‐randomized controlled studies (controlled clinical studies). </p> </section> <section id="CD011358-sec-0039"> <h4 class="title">Types of participants</h4> <p>Children and adults with SCD regardless of genotype such as sickle cell anaemia (HbSS), haemoglobin SC disease (HbSC) and S beta‐thalassaemia (Sβ+ and Sβ 0) and of both sexes were eligible for inclusion. </p> </section> <section id="CD011358-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Intravenous administration of Mg to children and adults (of any genotype) at any dose and any duration at hospital admission for acute pain crisis compared to either placebo or no supplementation (we regarded short term as less than four weeks). </p> <p>Oral administration of Mg to children and adults (of any genotype) at any dose and any duration (we regarded short term as less than four weeks and long term as from six months and less than two years) with at least one painful crisis in previous one year compared to either placebo or no supplementation. </p> </section> <section id="CD011358-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD011358-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011358-list-0001"> <li> <p>Change in frequency of vaso‐occlusive painful crises as measured by</p> <ol id="CD011358-list-0002"> <li> <p>pain diary of days with significant pain</p> </li> <li> <p>number of painful days (where the pain is strong enough to require analgesics)</p> </li> </ol> </li> <li> <p>Quality of life (measured using a validated scale)</p> </li> <li> <p>Length of hospital stay</p> </li> </ol> </p> </section> <section id="CD011358-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011358-list-0003"> <li> <p>Change in dense red cells in SCD</p> <ol id="CD011358-list-0004"> <li> <p>change in mean corpuscular haemoglobin concentration (MCHC)</p> </li> <li> <p>change in red cell distribution width (RDW)</p> </li> <li> <p>change in percentage of dense red cells (determined by phthalate density method)</p> </li> </ol> </li> <li> <p>Amelioration of hematological phenotype</p> <ol id="CD011358-list-0005"> <li> <p>haematological parameters (complete blood count (full blood count) including erythrocyte indices, reticulocyte percentage) </p> </li> <li> <p>biochemical parameters (blood urea nitrogen (BUN), creatinine, alanine amino transferase (ALT), aspartate amino transferase (AST) and blood chemistries using standard assays on a chemistry analyser) </p> </li> </ol> </li> <li> <p>Effects on K‐Cl co‐transport, red cell K+ and Mg2+ content (as determined with atomic absorption spectrometry (<a href="./references#CD011358-bbs2-0035" title="DeFranceschiL , BrugnaraC , Rouyer‐FessardP , JouaultH , BeuzardY . Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies. Blood1999;94(12):4307‐13. ">De Franceschi 1999</a>)) </p> <ol id="CD011358-list-0006"> <li> <p>erythrocytes</p> </li> <li> <p>potassium</p> </li> <li> <p>sodium</p> </li> </ol> </li> <li> <p>Adverse effects</p> <ol id="CD011358-list-0007"> <li> <p>mild, e.g. abdominal cramps, unpleasant flushing, nausea, vomiting, diarrhoea</p> </li> <li> <p>moderate, e.g. vomiting , nausea, feeling warmth, flushing, hypotension, bradycardia</p> </li> <li> <p>severe, e.g. cardiac arrhythmias, somnolence, double vision, slurred speech and weakness</p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD011358-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant published and unpublished studies without restrictions on language, year or publication status. </p> <section id="CD011358-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We identified relevant studies from the Cystic Fibrosis &amp; Genetic Disorders Group's Haemoglobinopathies Trials Register using the terms: (sickle cell OR (haemoglobinopathies AND general)) AND magnesium. </p> <p>The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library) and weekly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of last search: 03 February 2019.</p> <p>Using the search terms supplied in the appendices, we searched the clinical trial registries clinicaltrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>), WHO International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) and <i>meta</i> Register of Current Controlled Trials (<i>m</i>RCT) (<a href="http://www.controlled-trials.com/mrct/" target="_blank">www.controlled‐trials.com/mrct/</a>) (<a href="./appendices#CD011358-sec-0114">Appendix 1</a>). </p> <p>Date of last search: 04 April 2019.</p> <p>We searched the PubMed database (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>) for potentially relevant trials from 1946 to date (<a href="./appendices#CD011358-sec-0114">Appendix 1</a>). </p> <p>Date of last search: 04 April 2019.</p> </section> <section id="CD011358-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We also checked the references of the retrieved relevant articles to identify any additional studies. We made personal contact with experts and researchers in the field to ask for additional studies including unpublished and ongoing studies. </p> </section> </section> <section id="CD011358-sec-0047"> <h3 class="title" id="CD011358-sec-0047">Data collection and analysis</h3> <section id="CD011358-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two authors (NNT and HHKS) independently examined the titles and abstracts of the articles from electronic searches to remove any obviously irrelevant reports. The same two authors independently retrieved and reviewed full texts of the remaining articles to allow us to decide whether to include or exclude these according to the review's inclusion criteria. We were not blinded about the information of articles such as the journal of publication, the names of authors, the institution or the study results. We linked the multiple reports of the same study together. There was no disagreement about the inclusion of a study. However, if there are any disagreements in future, the two review authors will resolve the issue by discussion or by consulting a third review author (ALA). The review authors corresponded with other investigators, when required, to obtain further details of the study and missing information to clarify study eligibility and to allow a decision on the selection of studies. We listed the excluded studies with the reasons for exclusion in the <a href="./references#CD011358-sec-0124" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD011358-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two authors (NNT and HHKS) independently extracted the data from the studies which fulfilled the inclusion criteria using a standard data collection form and checked these for consistency. There were no disagreements; however, if there are any disagreements in future, we will resolve these by discussion. If required, we will consult with a third review author (ALA) to reach a consensus. We corresponded with original author(s) if the information in the published article was missing or not clear. One author (HHKS) entered data into the RevMan software (<a href="./references#CD011358-bbs2-0082" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and a second author (ALA) checked for any errors. </p> <p>We extracted the following information as far as possible:</p> <p> <ul id="CD011358-list-0008"> <li> <p>source (study ID (created by review author), report ID (created by review author), review author ID (created by review author), citation (journal or conference, year of publication, etc.), contact details); </p> </li> <li> <p>eligibility (confirmed eligibility for review or reason for exclusion);</p> </li> <li> <p>methods (study design, study setting, time and duration of study, sequence generation, allocation sequence concealment, blinding, other concerns about bias); </p> </li> <li> <p>participants (total number, eligibility criteria (inclusion and exclusion criteria), age and sex of participants); </p> </li> <li> <p>interventions (total number of intervention groups for each intervention and comparison group of interest: dose of intervention; routes of delivery; timing of administration; frequency of administration; duration of intervention; co‐interventions (if any)); </p> </li> <li> <p>outcomes (for each outcome of interest: outcome definition (diagnostic method, name of scale, definition of threshold); units of measurement (if relevant); for scales, upper and lower limits, and whether a high or low score is favourable); </p> </li> <li> <p>results (number of participants allocated to each intervention group, for each outcome of interest: sample size; missing participants; summary data for each intervention group (mean and standard deviation (SD) for continuous data, 2 x 2 table for dichotomous data, etc); </p> </li> <li> <p>miscellaneous (key conclusions of the study authors, references to other relevant studies; funding source; correspondence required). </p> </li> </ul> </p> <p>We extracted data from multiple reports of the same study directly into a single data collection form. We planned to group the outcome data into those measured at one month, up to three months, up to six months, up to one year and over one year. The data we are currently able to present are from the 'up to one month' period (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). For any studies included in future updates of the review, we will also record any outcome data which measured at other time periods (<a href="./references#CD011358-bbs2-0052" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> </section> <section id="CD011358-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (NNT and HHKS) independently assessed the risk of bias of included studies in seven domains as listed below. In each domain, we assigned a judgment of 'low risk', 'high risk' or 'unclear risk' of bias according to the criteria described in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD011358-bbs2-0053" title="HigginsJPT , AltmanDG , Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> <p> <ul id="CD011358-list-0009"> <li> <p>Sequence generation: low risk of bias (if the investigators included random component in sequence generation process such as using random number table, computer‐generated random number, coin tossing, shuffling cards or envelopes, etc.); high risk of bias (if the investigators included a non‐random component in sequence generation process such as the use of date of birth, date of admission, hospital or clinic record number, etc.); or unclear risk of bias (If there is no sufficient information about sequence generation process to judge whether high or low risk). </p> </li> <li> <p>Allocation concealment: low risk of bias (If the investigators used the methods such as central allocation, sequentially numbered drug containers of identical appearance, sequentially numbered opaque or sealed envelopes so that participants and investigator enrolling could not foresee the assignment); high risk of bias (If the investigators used an open random allocation schedule, non‐opaque envelops and any other quasi‐randomized methods such as alternation or rotation, case record number, etc. so that participants and investigator enrolling could possibly foresee the assignment); or unclear risk of bias (if method of concealment is not described or there is no sufficient information to judge whether high or low risk). </p> </li> <li> <p>Blinding of participants and personnel: low risk of bias (if blinding was done to the study participants or personnel and the method of blinding is described); high risk of bias (if no blinding or incomplete blinding was done to study participants and personnel); or unclear risk of bias (if there is no sufficient information to judge whether high or low risk). </p> </li> <li> <p>Blinding of outcome assessment: low risk of bias (if blinding was done to outcome assessors and method of blinding was described); high risk of bias (if blinding was not done to outcome assessors or if blinding was done, but likely it was broken); or unclear risk of bias (if there is no sufficient information to judge whether high or low risk). </p> </li> <li> <p>Incomplete outcome data: low risk of bias (no attrition, the number of dropouts or withdrawals was balanced in intervention groups with similar reasons); high risk of bias (imbalance of dropouts or withdrawals in intervention groups, the number and reasons of dropouts or withdrawals was not described); or unclear risk of bias: If there is no sufficient information of attrition or exclusions to judge whether high or low risk. </p> </li> <li> <p>Selective outcome reporting: low risk of bias (all the study's pre‐specified outcomes of interest were reported); high risk of bias (not all the study's pre‐specified outcomes of interest were reported, use of not pre‐specified measurement for assessing outcomes, incomplete reporting of outcome data); or unclear risk of bias (if there is no sufficient information to judge whether high or low risk). </p> </li> <li> <p>Other sources of bias: low risk of bias (the study appears to be free of other source of bias); high risk of bias (presence of other source of bias); or unclear risk of bias (if there is no sufficient information to judge whether high or low risk). </p> </li> </ul> </p> <p>The two review authors were not blinded to the names of study authors, institutions, journals and results of included studies. We discussed any discrepancies when assessing the risks of bias for a study. If we were not able to reach a consensus, we consulted a third review author (ALA). We contacted principal investigators to provide additional information which we thought was missing or unclear to allow us to make a risk of bias judgement. </p> </section> <section id="CD011358-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We reported dichotomous data (adverse events) using the risk ratio (RR) with 95% confidence intervals (CIs). We reported continuous data (pain scores, QoL and length of hospital stay) using the mean difference (MD) with 95% CIs for outcomes measured using the same scale between studies. If different studies had used different scales for measuring the same outcome, the review authors would have reported the standardized mean difference (SMD). </p> </section> <section id="CD011358-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>If the authors had included cluster‐randomized studies and if there had been little heterogeneity between all included studies, we would have pooled the results from both individually randomized studies and cluster‐randomized studies. </p> <p>For cross‐over studies, if we believed there was a carryover effect or where second‐period data were not available, we planned to include only data from the first period in the meta‐analysis (<a href="./references#CD011358-bbs2-0042" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). We contacted principle investigator of the De Montalembert cross‐over study to clarify where data were presented separately by time period, but investigators were unable to provide information regarding the time point (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). As we were not able to clarify whether these data are from the first or second period of time we have presented the results narratively and in the additional tables. </p> <p>In future updates of the review, if we include studies where there is no carry‐over effect and second period data are available, we will collect the mean difference of measurements on the experimental intervention (E) and on the control intervention (C) of each participant and its standard error (SE). We will include the effect estimate and its SE in the meta‐analysis using the generic inverse variance method in Review Manager (<a href="./references#CD011358-bbs2-0082" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>If, in future updates of the review, we identify and include studies with more than two intervention groups, we will determine the relevant groups and, if necessary, combine the relevant groups to create a single pair‐wise comparison. </p> </section> <section id="CD011358-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>Some of the studies we included have only been published in abstract form or presented at meetings or conferences. We therefore corresponded with the investigators to request full reports; we are still awaiting responses to allow us to draw our conclusions. We investigated attrition rates including dropouts, withdrawals and loss to follow up. For the missing or unclear data, or missing data with no reported reason for dropout, we contacted the study investigator to provide further information, but are still awaiting responses (<a href="./references#CD011358-bbs2-0054" title="HigginsJPT , DeeksJJ , Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011c</a>). </p> </section> <section id="CD011358-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the clinical, methodological and statistical heterogeneity of the included studies. For clinical heterogeneity, we assessed the variability in intervention, participants and outcomes studied. For methodological heterogeneity, we assessed the sequence generation, allocation concealment, blinding, and differences in outcome assessment. We used the Chi² test to determine statistical heterogeneity and we assessed P value less than 0.10 as statistically not significant. We were able to combine data from two studies for one adverse event (hypotension) and I² was 0% (no important heterogeneity) (<a href="./references#CD011358-fig-0008" title="">Analysis 1.5</a>) (<a href="./references#CD011358-bbs2-0040" title="DeeksJ , HigginsJ , Altman D on behalf of the Cochrane Statistical Methods Group. Chapter 9 Analysing data and undertaking meta‐analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>; <a href="./references#CD011358-bbs2-0051" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). </p> </section> <section id="CD011358-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We were able to compare four of the protocols of included studies with the final report of methods and results sections to identify the selective outcome reporting (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). We plan to use funnel plot in future updates (if we include at least 10 studies) to access the possibility of publication bias in studies, as recommended in chapter 10 of the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD011358-bbs2-0090" title="SterneJ , EggerM , Moher D on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1 [updated March 2011]. The CochraneCollaboration, 2011. Available from www.cochrane‐handbook.org. ">Sterne 2011</a>). If there is asymmetry, the possible causes of asymmetry may include true heterogeneity, high risk of bias or poor methodological quality, publication bias and selective outcome reporting. </p> </section> <section id="CD011358-sec-0056"> <h4 class="title">Data synthesis</h4> <p>The authors presented the available data from two of the included studies in a meta‐analysis using the RevMan software (<a href="./references#CD011358-bbs2-0082" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used a fixed‐effect model since we only combined data in a single instance; and the level of heterogeneity was not important. If, in future updates of the review, we are able to combine data from multiple studies and there is less than moderate heterogeneity among the included studies, we will continue to analyse the data using a fixed‐effect model. However, we will use a random‐effects model if we identify at least moderate heterogeneity (where the I² value is at 50% or more, which we regard as statistically significant heterogeneity). </p> </section> <section id="CD011358-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If, in future, the authors are able to include sufficient studies (at least 10) in a meta‐analysis and they identify at least 50% heterogeneity, we plan to undertake the following subgroup analyses: </p> <p> <ol id="CD011358-list-0010"> <li> <p>types of SCD (HbSS, HbSC disease, S β‐thalassaemia);</p> </li> <li> <p>demographic status (age less than 18 years or more than 18 years; male versus female);</p> </li> <li> <p>different doses of Mg supplementation (any dose used in oral or parenteral administration);</p> </li> <li> <p>different forms of Mg supplements (Mg pidolate, Mg sulphate, etc).</p> </li> </ol> </p> </section> <section id="CD011358-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>If we are able to include sufficient studies (at least 10) in a meta‐analysis, we plan to perform a sensitivity analysis where we exclude the studies judged to have a high risk of bias (e.g. high or unclear risk of bias in allocation concealment, blinding, incomplete outcome data). We will perform the meta‐analysis twice; firstly, including all studies and then including only studies that do not have a high risk of bias. We will also perform the meta‐analysis twice using firstly a fixed‐effect model and then a random‐effects model to assess how robust the findings are to the choice of analysis method. Finally, we will also perform sensitivity analysis to investigate the robustness of our conclusions when combining cluster‐randomized studies with individually randomized studies. We will report any sensitivity analyses of data by producing a summary table. </p> <section id="CD011358-sec-0059"> <h5 class="title">Summary of findings tables</h5> <p>In a post hoc change, we produced summary of findings tables using GRADE Profiler (<a href="./references#CD011358-bbs2-0046" title="www.gradepro.org . GRADEpro. Version 3.6.1. McMaster University, 2014. ">GRADEpro 2014</a>). We included one table for the comparison of intravenous Mg sulphate versus placebo (<a href="./full#CD011358-tbl-0001">summary of findings Table for the main comparison</a>) and one table for the comparison of oral Mg versus placebo (<a href="./full#CD011358-tbl-0002">summary of findings Table 2</a>). For the intravenous Mg table, we presented the outcomes: change in frequency of painful VOCs (measured by pain diary day of significant pain); length of hospital stay; child self‐reported QoL; hypotension; and warm at infusion site for intravenous Mg (<a href="./full#CD011358-tbl-0001">summary of findings Table for the main comparison</a>). For the oral Mg table we presented the outcomes: change in frequency of painful VOCs (measured by number of painful days); QoL; length of hospital stay; change in dense red cells; biochemical parameters; and adverse events (<a href="./full#CD011358-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011358-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011358-sec-0060"></div> <section id="CD011358-sec-0061"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD011358-sec-0123" title="">Characteristics of included studies</a> and <a href="./references#CD011358-sec-0124" title="">Characteristics of excluded studies</a>. </p> <section id="CD011358-sec-0062"> <h4 class="title">Results of the search</h4> <p>We identified 11 studies with 25 references in our searches, five studies (16 references) were included (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). Five studies were excluded each with one full‐text article (<a href="./references#CD011358-bbs2-0006" title="BrousseauDC , ScottJP , HilleryCA , PanepintoJA . The effect of magnesium on length of stay for pediatric sickle cell pain crisis. Academic Emergency Medicine2004;11(9):968‐71. ">Brousseau 2004</a>; <a href="./references#CD011358-bbs2-0007" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , AlperS , et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. Journal of Clinical Investigation1997;100(7):1847‐52. ">De Franceschi 1997</a>; <a href="./references#CD011358-bbs2-0008" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , NeubergD , et al. Oral magnesium pidolate: effects of long‐term administration in patients with sickle cell disease. British Journal of Haematology2000;108(2):284‐9. ">De Franceschi 2000</a>; <a href="./references#CD011358-bbs2-0009" title="HankinsJS , WynnLW , BrugnaraC , HilleryCA , LiCS , WangWC . Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. British Journal of Haematology2007;140(1):80‐5. ">Hankins 2007</a>; <a href="./references#CD011358-bbs2-0010" title="YousifOO , HassanMK , Al‐NaamaLM . Red Blood Cell and Serum Magnesium Levels Among Childrenand Adolescents With Sickle Cell Anemia. Biol Trace Elem Res2018;186(2):295‐304. ">Yousif 2018</a>). One study (with two abstracts) is listed as 'Awaiting classification' and will be either included or excluded when we have further information (<a href="./references#CD011358-bbs2-0011" title="NodarosK , VoskaridouE , Atta‐PolitisJ , LoukopoulosD . Administration of magnesium aspartate in patients with HbS/ß‐thalassaemia normalizes the RBC density distribution and removes dense sickle cells from the peripheral blood [abstract]. Blood1999;94(10 Suppl 1):200a. [CFGD Register: SC109a] VoskaridouE , NodarosK , Atta‐PolitisJ , LoutradiA , LoukopoulosD . Administration of magnesium aspartate in patients with HbS/b‐thalassaemia results in normalization of the red cell density distribution curves and removal of the dense sickle cells from the peripheral blood [abstract]. 5th Congress of the European Haematology Association (EHA), 2000 June 25‐28; Birmingham, UK. 2000. [CENTRAL: 302987; CFGD Register: SC109b; CRS: 5500100000001715] ">Voskaridou 2000</a>). This process is detailed in the PRISMA diagram (<a href="#CD011358-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011358-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011358-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011358-sec-0063"> <h4 class="title">Included studies</h4> <p>There are three included studies for oral Mg treatment (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>) and two included studies for intravenous Mg in treating people with SCD (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). The number of participants in the studies of oral Mg ranged from 12 children (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>) to 24 children (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>); and in the studies of intravenous IV Mg ranged from 104 children (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>) to 202 participants (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). </p> <p><b>Trial design</b> </p> <p>All five included studies were randomized; three were of parallel design (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>) and two were of cross‐over design (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). Four of the studies had two treatment arms (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>), but one compared four separate treatment groups (factorial design) (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). Two studies were short‐term studies of people admitted to the emergency department for a VOC (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>), but the remaining three studies were of longer duration (at least six months of treatment) and outpatient‐based (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). One study was conducted in Europe (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>), one in Canada (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>) and three in the USA (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a><a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> <p><b>Participants</b> </p> <p>The numbers of participants in the two intravenous Mg studies (202 (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>) and 104 (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>)) were greater than in the oral Mg studies (which ranged from 12 (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>) to 24 children (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>)). Three studies included only paediatric participants (i.e. up to 18 years of age) (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>) and two studies included both adults and children; one with an age range of five to 53 years, although 73% of participants were under the age of 16 (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>) and the final study recruited participants aged between four and 21 years; 60% were in the stratified age group of 12 to 21 years old (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). All five studies reported on the gender split of participants and in all studies there were more males than females. In four of the studies the split was almost equal (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>), but in one study there were significantly more males (71%) than females (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). For the three long‐term studies, all participants had experienced at least one VOC in the previous 12 months (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). One study described participants as having SCD (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>); two studies specified participants had HbSC (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>); the fourth study included a range of participants: 61 (58.6%) had homozygous sickle cell anaemia; 33 (31.7%) had sickle haemoglobin C disease; and 10 (9.6%) had sickle beta thalassaemia (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>) and the fifth study reported that 92 participants (91%) in the Mg group had HgbSS and 98 participants (95%) in the control group had HgbSS (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). </p> <p>There is a discrepancy in the stated number of participants in Goldman study between the two publications relating to this study (MAST study‐ NCT00313963); the 2011 paper states that 107 participants were randomized and 104 included in the study, but the 2013 paper states that 106 participants were included (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). There is also a discrepancy in the number of participants described in the MAGiC study (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). The primary paper states that 202 participants were enrolled (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>); however a paper by Brandow reporting secondary data analysis of this study looking at opoid used (in emergency department and during hospital admission) reported 204 participants were enrolled. We have contacted the authors of both studies for further clarification. </p> <p><b>Interventions</b> </p> <p>A summary of the interventions is presented in the additional tables (<a href="#CD011358-tbl-0003">Table 1</a>). </p> <div class="table" id="CD011358-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Interventions in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial design</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous Mg sulphate</p> <p>Dosage: 8‐hourly doses of 100 mg/kg, maximum of 2 g per dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo (saline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomized parallel study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous Mg sulphate</p> <p>Dosage: 40 mg/kg (max 2.4 g). Infused at a concentration of 40 mg/mL, 8‐hourly, total of 6 doses </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo (normal saline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomized parallel study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral Mg pidolate</p> <p>Liquid</p> <p>Dosage: 0.3 mmol/kg/day in twice daily doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo or hydroxyurea</p> <p>(data from comparison of Mg versus hydroxyurea not eligible for inclusion in this review) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomized parallel study (factorial design)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral Mg pidolate</p> <p>Blisters containing 1500 mg of pyrolidone carboxylate of Mg</p> <p>Dosage: 1, 2, 3 or 4 blisters per day depending on weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomized cross‐over study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a> </p> <p>(NCT 00040456)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral Mg pidolate</p> <p>Liquid</p> <p>Dosage: 0.6 meq Mg pidolate/kg body weight per day divided into 2 daily doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomized cross‐over study</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Mg: magnesium</p> </div> </div> <p>All five studies compared the active intervention to a placebo control group (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>); one study additionally compared oral Mg pidolate to oral hydroxyurea (these data are not presented in this review as we are only comparing Mg to placebo or no treatment) (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). </p> <p>Two studies treating participants for a painful crisis compared intravenous Mg sulphate to saline (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). The doses were both given every eight hours, but differed in volume; one study administered 40 mg/kg to a maximum of 2.4 g with a maximum total of six doses until discharge (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>) and the second administered 100 mg/kg to a maximum of 2 g per dose (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). </p> <p>Three studies used oral Mg pidolate as the active intervention (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). One study used once‐daily blisters whose tablets containing 1500 mg of pyrolidone carboxylate of Mg; the number of tablets (and therefore the amount of treatment drug) depended on the weight of the participant (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). Two studies gave twice‐daily doses of Mg pidolate in liquid form (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). The doses were 0.6 meq Mg pidolate/kg body weight per day (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>) and 0.3 mmol/kg/day (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). </p> <p><b>Outcomes</b> </p> <p>Three of the studies reported on the review's primary outcome of pain (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>); but the study of intravenous Mg sulphate for the relief of a VOC had a slightly different focus than the longer‐term studies and only looked at the mean daily pain intensity and cumulative analgesic requirement (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). Two studies reported on the number of painful days (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>), one of these studies additionally reported on pain intensity and the amount of analgesic administered (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). One study reported on the review's second primary outcome HRQoL (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>); length of hospital stay (third primary outcome) was reported by two the short‐term studies (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). The secondary outcome measures of changes in dense red cell and amelioration of hematological phenotype outcome measures were not reported by any of the included studies (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). Effects of Mg2+ content was reported by one study (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). Three studies reported adverse events but not split according to severity as we had planned to report (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> </section> <section id="CD011358-sec-0064"> <h4 class="title">Excluded studies</h4> <p>We excluded five studies since none of them were randomized (<a href="./references#CD011358-bbs2-0006" title="BrousseauDC , ScottJP , HilleryCA , PanepintoJA . The effect of magnesium on length of stay for pediatric sickle cell pain crisis. Academic Emergency Medicine2004;11(9):968‐71. ">Brousseau 2004</a>; <a href="./references#CD011358-bbs2-0007" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , AlperS , et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. Journal of Clinical Investigation1997;100(7):1847‐52. ">De Franceschi 1997</a>; <a href="./references#CD011358-bbs2-0008" title="DeFranceschiL , BachirD , GalacterosF , TcherniaG , CynoberT , NeubergD , et al. Oral magnesium pidolate: effects of long‐term administration in patients with sickle cell disease. British Journal of Haematology2000;108(2):284‐9. ">De Franceschi 2000</a>; <a href="./references#CD011358-bbs2-0009" title="HankinsJS , WynnLW , BrugnaraC , HilleryCA , LiCS , WangWC . Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. British Journal of Haematology2007;140(1):80‐5. ">Hankins 2007</a>; <a href="./references#CD011358-bbs2-0010" title="YousifOO , HassanMK , Al‐NaamaLM . Red Blood Cell and Serum Magnesium Levels Among Childrenand Adolescents With Sickle Cell Anemia. Biol Trace Elem Res2018;186(2):295‐304. ">Yousif 2018</a>) (see <a href="./references#CD011358-sec-0124" title="">Characteristics of excluded studies</a>). </p> <section id="CD011358-sec-0065"> <h5 class="title">Studies awaiting classification</h5> <p>There is only one controlled clinical study which is listed as awaiting classification (<a href="./references#CD011358-bbs2-0011" title="NodarosK , VoskaridouE , Atta‐PolitisJ , LoukopoulosD . Administration of magnesium aspartate in patients with HbS/ß‐thalassaemia normalizes the RBC density distribution and removes dense sickle cells from the peripheral blood [abstract]. Blood1999;94(10 Suppl 1):200a. [CFGD Register: SC109a] VoskaridouE , NodarosK , Atta‐PolitisJ , LoutradiA , LoukopoulosD . Administration of magnesium aspartate in patients with HbS/b‐thalassaemia results in normalization of the red cell density distribution curves and removal of the dense sickle cells from the peripheral blood [abstract]. 5th Congress of the European Haematology Association (EHA), 2000 June 25‐28; Birmingham, UK. 2000. [CENTRAL: 302987; CFGD Register: SC109b; CRS: 5500100000001715] ">Voskaridou 2000</a>). The study was published as an abstract only which does not allow us to adequately assess the design against our inclusion criteria. The study included 10 adults who were diagnosed with β<sup>S</sup>/β thalassaemia disease. Five adults received 0.6 mE/kg/day of oral of Mg aspartate for six months (after informed consent) and a further five adults received a placebo for six months. The outcomes measured were an arbitrary scoring of clinical severity; follow up of main red cell parameters along with the level of intracellular and serum Mg and the density of red cell distribution. </p> </section> </section> </section> <section id="CD011358-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, we judged the included studies to have a moderate risk of bias (<a href="#CD011358-fig-0002">Figure 2</a>; <a href="#CD011358-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD011358-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011358-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011358-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011358-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011358-sec-0067"> <h4 class="title">Allocation</h4> <section id="CD011358-sec-0068"> <h5 class="title">Sequence generation</h5> <p>Two of the included studies were judged to have an unclear risk of bias for sequence generation as neither study described the method of randomization (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). The De Montalembert study states that participants were randomly allocated to one of the two arms ‐ either six months of Mg pidolate followed by a three‐month washout period and then six months of placebo or the reverse order (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). The Mueller study states that participants were randomized to either receive oral Mg pidolate or placebo for six months followed by a washout period and six months of the other agent with a further washout period (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> <p>We judged three studies to have a low risk of bias for sequence generation (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). In the MAGiC study, randomization tables were provided by the data co‐ordinating centre and used randomly varying block sizes for equal allocation stratified by age group, study site and hydroxyurea use during past three months (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). In the Goldman study, participants were also randomly assigned to treatment group by the research pharmacy using preset randomization tables (blocks of four) (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). In the CHAMPS study the allocation sequence was generated using a sequential allocation algorithm (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). </p> </section> <section id="CD011358-sec-0069"> <h5 class="title">Allocation concealment</h5> <p>The two studies which had an unclear risk of bias for sequence generation also had an unclear risk of bias for allocation concealment, again due to a lack of clear information (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>).The two studies with a low risk of bias for sequence generation, were also graded as having a low risk of bias for allocation concealment (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). In the MAGiC study, a central randomization service was used where the randomization tables were provided by PECARN data co‐ordinating centres to the research pharmacy preparing the drugs at each study site (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). In the Goldman study, the sequence was generated by the research pharmacy (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). Following contact with the de Montalembert study authors, it was confirmed that treatments were allocated by a central randomization service, therefore we graded this study as having a low risk of bias also (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). </p> </section> </section> <section id="CD011358-sec-0070"> <h4 class="title">Blinding</h4> <p>The De Montalembert study was described as being double‐blind, but there was no description of the placebo or any further information in the abstract to allow us to make a clear judgement; therefore, we contacted the lead author who confirmed that there was a full blinding of participants and personnel as treatment and placebo were not distinguishable and we have graded this study as having an low risk of bias for blinding of participants, personnel and outcome assessors (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). We graded the remaining four studies as having a low risk of bias for participants and personnel as they are all described as being double‐blind and give descriptions of placebo treatments that were indistinguishable from the study medication (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). However, we graded these four studies as having an unclear risk of bias for blinding of outcome assessors since, although they were described as being double blind and in some cases it was stated (e.g. on a trial registry) that blinding included outcome assessors, no further details were given (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>; <a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). </p> </section> <section id="CD011358-sec-0071"> <h4 class="title">Incomplete outcome data</h4> <p>We graded one included study as having a high risk of attrition bias (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). The CHAMPS study enrolled 64 participants and 44 of these were randomized; 36 participants completed eight weeks of the study but only 22 participants completed the full 44 weeks providing data for the primary end point (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). We graded one included study as having an low risk of attrition bias (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). The number of participants in the De Montalembert study was stated in the abstract as 24 with no mention of the number randomized or if there were any withdrawals, but the lead author later confirmed that 24 participants were randomized and there were no withdrawals (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). However, we judged the remaining three studies as having low risk of attrition bias (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). In the MAGiC study, 208 children were randomized and 204 children received study drug (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). In the Goldman study, 106 children were randomly assigned to treatment arms in the study, 104 participants were included (two withdrew consent) and 98 provided data (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). In the Mueller study, only five out of 12 participants were evaluated for efficacy; however, reasons were given for the seven participants who dropped out: three for non‐compliance, two for study violation (pharmacy dispensed wrong formulation) and two withdrew citing personal reasons (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> </section> <section id="CD011358-sec-0072"> <h4 class="title">Selective reporting</h4> <p>The study protocol for the De Montalembert study was not available, we therefore judged this study to have an unclear risk of bias for selective outcome reporting (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). </p> <p>The remaining four included studies had protocols available from the online trial registry clinicaltrials.gov showing a history of changes: </p> <p> <ul id="CD011358-list-0011"> <li> <p><a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a> (NCT00532883 ‐ since 20 September 2007); </p> </li> <li> <p><a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a> (NCT00313963 ‐ since 10 April 2006); </p> </li> <li> <p><a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a> (NCT01197417 ‐ since 31 August 2010); and </p> </li> <li> <p><a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a> (NCT00040456 ‐ since 26 June 2002). </p> </li> </ul> </p> <p>To date, the Mueller study has only been presented as a poster with no full paper publication (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). We have contacted the primary investigator of the study for information to allow us to assess reporting bias, but we are still waiting for the reply. In the study protocol, the stated primary outcome was to evaluate whether treatment with oral Mg pidolate decreases the number of painful crises; secondary outcomes were tolerance of long‐term treatment with oral Mg pidolate and the effects of Mg pidolate therapy on K‐Cl co‐transport activity, red blood cell (RBC) hydration status and the intracellular Mg content of erythrocytes. Only limited adverse event data were reported in the poster presentation of this study, but efficacy data were due at a later date (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). We judged this study to have an unclear risk of bias due to insufficient information to allow a judgement. </p> <p>Three of the studies had corresponding full paper publications and we judged them to have a low risk of bias as they reported their pre‐specified outcome measures (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). </p> <p>The primary outcome of the MAGiC study was length of hospital stay (hours); the secondary outcomes were morphine use during hospitalizations, adverse events (during infusion and development of acute chest syndrome) and health‐related QoL (both during and after study drug infusion) (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). The primary outcome of the Goldman study was also length of hospital stay; the secondary outcomes were a reduction of mean daily pain score during an admission for a sickle cell pain crisis, adverse events during admission and the cumulative volume of a narcotic drug required to manage the crises during admission (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). The primary outcome of the CHAMPS study was the proportion of hyperdense red blood cells (red blood cells with density greater than 41 g/dL); secondary outcomes were to document the toxicity of both drugs (Mg and hydroxyurea) and their effects on hematological parameters and red cell metabolism in people with SCD (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). </p> </section> <section id="CD011358-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <p>We judged only one study to have a low risk of potential bias where the author later confirmed that the authors compared the data observed during the placebo periods (the first period for half of the participants and the second period for the remaining participants) and those observed during the treatment periods (the first period for half of the participants and the second period for the remaining participants) (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). </p> <p>We judged two of the included studies to have a high risk for other potential sources of bias (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). In the Goldman study, the targeted sample size expected from protocol was not achieved. The estimated enrolment ranged from 120 to 126 (see history of changes of NCT00313963 on <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). The earlier abstract of the Goldman study published in 2011 reported 107 individuals were randomized and 106 participated in the study. The full study publication states that a total of 159 people were approached to participate in the study, 106 (67%) consented and two participants (2%) withdrew their consent to participate in the study (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). In the Wang study, the original sample size calculation was 188 participants across four treatment arms (see the NCT00532883 record registered on 01 September 2005 on <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>), but the enrolment of participants in this Phase II trial between January 2007 and August 2009 was only 44 (according to the last‐updated version of the NCT00532883 record from January 2010). The full Wang paper states that 64 participants enrolled and 44 of these were randomized; a total of 36 participants completed the eight weeks of study (the primary end point evaluation), but only 22 participants completed 44 weeks of treatment. The study was terminated early because of the slow enrolment (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). </p> <p>The authors judged there to be an unclear risk from other potential sources of bias for two studies (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). In the Brousseau study, blood Mg levels were not measured before and after intravenous Mg therapy, so Mg toxicity was not monitored (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). Also the targeted sample size calculation for the Brousseau study was 104 per arm with a total of 208 (see history of changes on <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> for NCT01197417). In the original full publication, 410 potential participants were approached and 208 were randomized. However, there are differences in the number of participants described in the secondary data analysis of the MAGiC study by Brandow, where 204 participants were stated as being enrolled. Due to the lack of measurement of Mg blood levels, we judged this study have an unclear for other potential sources of bias (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). The Mueller study expected to enrol 20 participants; 100 eligible potential participants were contacted and invited to participate in the study, but according to the current recruiting status on <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>, the number of participants recruited is 12 and the study was terminated due to lack of accrual. A full paper has not been published and the results for 12 participants have only been presented narratively without data analyses (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> </section> </section> <section id="CD011358-sec-0074"> <h3 class="title" id="CD011358-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD011358-tbl-0001"><b>Summary of findings for the main comparison</b> Intravenous magnesium sulphate versus placebo for treating sickle cell disease</a>; <a href="./full#CD011358-tbl-0002"><b>Summary of findings 2</b> Oral magnesium pidolate versus placebo/no intervention for treating sickle cell disease</a> </p> <section id="CD011358-sec-0075"> <h4 class="title">Intravenous Mg sulphate versus control</h4> <p>Two studies (n = 306) compared intravenous Mg sulphate to saline for treating people admitted to hospital with a VOC (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). </p> <section id="CD011358-sec-0076"> <h5 class="title">Primary outcomes</h5> <section id="CD011358-sec-0077"> <h6 class="title">1. Change in frequency of vaso‐occlusive painful crises</h6> <section id="CD011358-sec-0078"> <p><b>a. pain diary of days with significant pain</b></p> <p>In the Goldman study, a total of 98 participants provided data for 104 painful episodes. The mean daily pain intensity during hospitalisation was measured for the Mg sulphate and placebo groups using the Faces Pain Scale–Revised, which has been validated for children between four and 18 years of age (<a href="./references#CD011358-bbs2-0050" title="HicksCL , vonBaeyerCL , SpaffordPA , vanKorlaarI , GoodenoughB . The Faces Pain Scale‐Revised: toward a common metric in pediatric pain measurement. Pain2001;93(2):173–83. ">Hicks 2001</a>). There was no significant difference between the groups, MD 0.10 (95% CI ‐0.82 to 1.02) (<a href="./references#CD011358-fig-0004" title="">Analysis 1.1</a>). </p> <p>This outcome was not reported by the second included study (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). </p> </section> <section id="CD011358-sec-0079"> <p><b>b. number of painful days (where the pain is strong enough to require analgesics)</b></p> <p>The secondary data analysis of MAGiC study by Brandow reported the standard opoid treatment for acute pain events and LOS. The mean total initial dose of opoid was 0.043 (0.029) mg/kg/hour and was administered over a median of 8.5 (interquartile range (IQR) 6.4 to 13.1) hours. The median time to first IV opoid was 1.02 (IQR 0.65 to 1.33) hours; the median time to first oral opioid was 28.3 (IQR 12.2 to 61.1) hours. These data and route of administrations for opoid used were not separately mentioned either with Mg or placebo in this paper by Brandow (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). </p> <p>This outcome was not reported by Goldman (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). </p> </section> </section> <section id="CD011358-sec-0080"> <h6 class="title">2. Quality of life (measured using a validated scale)</h6> <p>The MAGiC study assessed health‐related QoL with both child‐reported and parent‐reported scales ‐ the PedsQL generic core scales, PedsQL multi‐dimensional fatigue scales and PedsQL SCD (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). There was no significant difference in any child self‐reported scores (from ED to pre‐discharge and one week follow up) between the Mg and placebo groups (<a href="./references#CD011358-fig-0005" title="">Analysis 1.2</a>). Likewise for the parent self‐reported scores from the different scales, there were no differences shown between the Mg and the placebo groups (<a href="./references#CD011358-fig-0006" title="">Analysis 1.3</a>). This outcome was not reported by the second included study (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). </p> </section> <section id="CD011358-sec-0081"> <h6 class="title">3. Length of hospital stay</h6> <p>Brousseau reported the median length of stay which included the total time until discharge from the hospital regardless of the time of last opoid (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). There was no difference in length of stay between the Mg and placebo groups. A post hoc analysis evaluating whether Mg had an effect on the length of stay, if the child presented early in the course of the pain crisis, also reported no difference in this outcome between the treatment or the placebo groups (<a href="#CD011358-tbl-0004">Table 2</a>). </p> <div class="table" id="CD011358-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Length of stay (hours)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study: </b><a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] "><b>MAGiC 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Magnesium Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOS: median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.0 (27.0 ‐ 109.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.0 (24.0 ‐ 99.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOS: total time until discharge from hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.5 (40.0 ‐ 124.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.5 (37.0 ‐ 122.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOS: early in the course of the pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.0 (30.0 ‐ 113.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.0 (23.0 ‐ 92.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.49</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IQR: interquartile range<br/> LOS: length of stay </p> </div> </div> <p>Goldman also reported the length of hospital stay counted as the number of hours from the first study dose until the physician's decision to discharge the participant (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). This time correlates most closely with the termination of intravenous analgesia. There was no statistically significant difference between the Mg group and the control (saline) group in length of hospital stay, MD 14.70 hours (95% CI ‐20.51 to 49.91) (<a href="./references#CD011358-fig-0007" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD011358-sec-0082"> <h5 class="title">Secondary outcomes</h5> <section id="CD011358-sec-0083"> <h6 class="title">1. Change in dense red cells</h6> <p>Neither included study reported any measure of the change in dense red cells (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). </p> </section> <section id="CD011358-sec-0084"> <h6 class="title">2. Amelioration of hematological phenotype</h6> <p>Neither included study reported on this outcome (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). </p> </section> <section id="CD011358-sec-0085"> <h6 class="title">3. Effects on K‐Cl co‐transport, red cell K+ and Mg2+ content</h6> <p>Neither included study reported on this outcome (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). </p> </section> <section id="CD011358-sec-0086"> <h6 class="title">4. Adverse effects</h6> <p>Both studies (n = 306) reported a number of adverse events but did not categorise them as mild, moderate or severe as we planned to report (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). We therefore present adverse event data in summary and not by severity. When entered into analysis, there was only one significant difference adverse event (warmth at infusion site), but there were no significant differences for other adverse events between the treatment and control arms (<a href="./references#CD011358-fig-0008" title="">Analysis 1.5</a>). </p> </section> </section> </section> <section id="CD011358-sec-0087"> <h4 class="title">Oral magnesium pidolate versus control</h4> <p>Three studies (n = 80) compared oral Mg pidolate to control (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). The CHAMPS paper stated a minimum and maximum number of participants at baseline and each visit for those receiving hydroxyurea with Mg or with Mg placebo which ranged from 20 to 23 at baseline, 13 to 17 at week 8 and 12 to 13 at week 24; it also stated the same for those participants receiving placebo hydroxyurea with either Mg or Mg placebo which ranged from 19 to 21 at baseline, 17 to 19 at week 8 and 13 to 14 at week 24 (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). There is no meta‐analysis performed and results are summarised narratively for outcomes comparing oral Mg and placebo group. </p> <section id="CD011358-sec-0088"> <h5 class="title">Primary outcomes</h5> <section id="CD011358-sec-0089"> <h6 class="title">1. Change in frequency of vaso‐occlusive painful crises</h6> <section id="CD011358-sec-0090"> <p><b>a. pain diary of days with significant pain</b></p> <p>Only one cross‐over study (n = 24) described the change in frequency of VOC (number of painful days) (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). The mean (SD) (range) number of days of pain during the six‐months period in the Mg group was 8.6 (12.4) (0 to 41) days and in the placebo group was 10.5 (12.4) (0 to 54) days. There was no significant difference in the number of painful days between the Mg treatment group and placebo, MD 1.90 days (95% CI ‐1.05 to 4.85) (low quality evidence) (<a href="./references#CD011358-fig-0009" title="">Analysis 2.1</a>). </p> <p>The remaining two studies in this comparison did not report on this outcome (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> </section> <section id="CD011358-sec-0091"> <p><b>b. number of painful days (where the pain is strong enough to require analgesics)</b></p> <p>This outcome was not reported by any of the included studies for this comparison (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> </section> </section> <section id="CD011358-sec-0092"> <h6 class="title">2. Quality of life</h6> <p>This outcome was not reported by any of the included studies for this comparison (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> </section> <section id="CD011358-sec-0093"> <h6 class="title">3. Length of hospital stay</h6> <p>This outcome was not reported by any of the included studies for this comparison (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> </section> </section> <section id="CD011358-sec-0094"> <h5 class="title">Secondary outcomes</h5> <section id="CD011358-sec-0095"> <h6 class="title">1. Change in dense red cells in SCD</h6> <p>This outcome was not reported by any of the included studies for this comparison (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> </section> <section id="CD011358-sec-0096"> <h6 class="title">2. Amelioration of hematological phenotype</h6> <p>This outcome was not reported by any of the included studies for this comparison (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> </section> <section id="CD011358-sec-0097"> <h6 class="title">3. Effects on K‐Cl co‐transport, red cell K+ and Mg2+ content</h6> <p>Only the CHAMPS study reported on K‐Cl co‐transport activity and measured chloride‐dependent net K efflux (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). No values for the SDs were available from this study for K‐Cl co‐transport content effects which would have allowed us to undertake a meta‐analysis; we have therefore presented the available information in the additional tables (<a href="#CD011358-tbl-0005">Table 3</a>). </p> <div class="table" id="CD011358-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Effects on K‐Cl cotransport, red cell K+ and Mg2+ content</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Study: </b><a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] "><b>CHAMPS 2011</b> </a> </p> <p><b>Ion content</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>No Mg</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>N (minimum, maximum)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>N (minimum, maximum)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(20, 23)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(13, 17)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(12, 13)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(19, 21)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(17, 19)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(13, 14)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Week 8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Week 24</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Week 8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Week 24</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plasma ionized Mg (mmol/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plasma total Mg (mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>K‐Cl co‐transport (mmol/10<sup>13</sup>cells x h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cell Na (mmol/kg Hb)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cell K (mmol/kg Hb)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>236</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Both mean levels of plasma ionised Mg and plasma total Mg at week 8 were slightly greater compared to placebo (P value = 0.02 for ionised Mg) (P value = 0.04 for total Mg). </p> <p>Cl: chloride<br/> Hb: haemoglobin<br/> K: potassium<br/> Mg: magnesium<br/> Na: sodium </p> </div> </div> <section id="CD011358-sec-0098"> <p><b>a. Erythrocytes</b></p> <p>The CHAMPS study determined the Mg content of erythrocytes by atomic absorption spectrophotometry (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). The mean Mg levels at week eight were slightly higher in the Mg group compared with those receiving placebo (<a href="#CD011358-tbl-0005">Table 3</a>). </p> <p>De Montalembert measured the RBC Mg levels every three months (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). The mean (SD) (range) values for RBC Mg during the six months in the Mg group were 7.19 (2.02) (4.81 to 14.8) mM/kg Hb and in the placebo group were 6.73 (1.14) (4.95 to 9.32) mM/kg Hb (P value = 0.24). When analysed, there was no significant difference Mg in erthrocytes between the two groups, MD 0.46 mM/kg Hb (95% CI ‐0.29 to 1.21) (low quality evidence) (<a href="./references#CD011358-fig-0010" title="">Analysis 2.2</a>). </p> <p>The third included study planned to report on "change in the intracellular Mg content of erythrocytes" as one of the secondary outcomes, but the available poster presentation did not present data for this outcome (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> </section> <section id="CD011358-sec-0099"> <p><b>b. potassium</b></p> <p>In the CHAMPS study, the potassium content of erythrocytes was determined by atomic absorption spectrophotometry (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). Again the published report did not provide values for the SDs for K+ content effect, so we are not able to perform a meta‐analysis. Available results are presented in the additional tables (<a href="#CD011358-tbl-0005">Table 3</a>). The two remaining included studies for this comparison did not report on this outcome (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> </section> <section id="CD011358-sec-0100"> <p><b>c. sodium</b></p> <p>In the CHAMPS study, the sodium content of erythrocytes was determined by atomic absorption spectrophotometry (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). As before, no SDs were reported and we were not able to undertake a meta‐analysis; the available results are presented in the additional tables (<a href="#CD011358-tbl-0005">Table 3</a>). The two remaining included studies for this comparison did not report on this outcome (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> </section> </section> <section id="CD011358-sec-0101"> <h6 class="title">4. Adverse effects</h6> <p>Adverse events were not reported in the De Montalembert study (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). In the Mueller study, which has only been published as a scientific meeting abstract, investigators report some narrative information on adverse events. The report states that there were seven events probably related to the study drug or placebo, but only one episode of diarrhoea was severe or worse (described by the paper as grade 3 or higher). There were a further eight events which were possibly related to the study drug or placebo: diarrhoea in three participants (none severe or disabling (described as grade 3 or 4)); and headache in five participants (two were disabling (grade 4) and three were severe (grade 3)). All adverse events resolved without stopping treatment (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> <p>In the CHAMPS study, a total of 38 participants reported 293 adverse events while receiving study drugs. Of these, 22 events in 10 participants were reported as serious adverse events, but no differences were observed across the four treatment groups in the distribution of these events. Fifteen of the reported serious adverse events (in nine participants) and 111 of the adverse events (in 27 participants) were described as VOCs, but there were no significant differences among groups. Participants also reported 42 occurrences of gastrointestinal disorders, 22 episodes of headache or migraine, 18 upper respiratory infections and nine episodes of rash. There were no deaths during the 26.3 participant years of follow‐up (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011358-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011358-sec-0102"></div> <section id="CD011358-sec-0103"> <h3 class="title" id="CD011358-sec-0103">Summary of main results</h3> <p>There were five randomized controlled studies (n = 386) included in this review (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). Two parallel studies examined short‐term intravenous Mg (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>) and three studies examined longer‐term oral Mg; one of these was of parallel design with four arms comparing oral Mg pidolate to hydroxyurea and respective placebos (only the Mg pidolate versus placebo comparison was eligible for inclusion in this review) (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>) and two were of cross‐over design (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> <p>Only one of the two studies reporting on intravenous Mg use (n = 104) reported analysable data for pain score (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). There was no difference found between Mg sulphate or placebo groups for pain score at up to one month, MD 0.10 (95% CI ‐0.82 to 1.02) (<a href="./references#CD011358-fig-0004" title="">Analysis 1.1</a>). The second study of intravenous Mg (n = 202) reported analysable change data for HRQoL scores between arrival at the emergency department to pre‐ discharge and one week follow‐up, we found there was no significant difference between Mg and placebo groups in child self‐reported scores (<a href="./references#CD011358-fig-0005" title="">Analysis 1.2</a>) or parent self‐reported score (<a href="./references#CD011358-fig-0006" title="">Analysis 1.3</a>). Both studies reported on the length of hospital stay, but data were only analysable from one study (n = 104) (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>) and showed no difference between the groups, MD 14.70 hours (95% CI ‐20.51 to 49.91) (<a href="./references#CD011358-fig-0007" title="">Analysis 1.4</a>). Both studies also reported a number of adverse events but did not categorise them as mild, moderate or severe as we had planned to report. We therefore present adverse event data in general and not by severity. There was significant association of warmth at infusion site between the intravenous Mg sulphate group and the placebo group, but there was no significant difference in hypotension, nausea or vomiting, pain at the infusion site, pruritus, tachycardia, drowsiness and acute chest syndrome (<a href="./references#CD011358-fig-0008" title="">Analysis 1.5</a>). From our analysis, there was no clear benefit, but some harm (warmth at infusion site) identified with intravenous Mg sulphate compared to placebo (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). </p> <p>One cross‐over study (n = 24) comparing oral Mg pidolate to placebo reported on one of our primary outcomes (change in frequency of painful crisis) and one secondary outcome (Mg levels in red blood cells); there was no significant difference reported in painful days and Mg levels in RBC between the Mg treatment group and placebo group in the six‐month study (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). The parallel CHAMPS study (n = 44) reported effects of oral Mg pidolate and placebo on K‐Cl co‐transport, sodium and potassium ion transport measures but we were not able to analyse these due to insufficient information (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). We were not able to analyse any adverse event data. One study reported no adverse events (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>) and a second study reported limited narrative on adverse events all of which resolved without stopping treatment (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). The third study reported that no differences were observed across the four treatment groups in the distribution of adverse events such as VOCs, gastrointestinal disorders, headache or migraine, upper respiratory infection or rash; there were no deaths reported (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). </p> </section> <section id="CD011358-sec-0104"> <h3 class="title" id="CD011358-sec-0104">Overall completeness and applicability of evidence</h3> <p>Two parallel studies of intravenous Mg sulphate reported on our all primary outcomes of pain score and length of stay in hospital in hours and quality of life (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). Only one of the studies comparing oral Mg pidolate to placebo measured our primary outcome of change in the frequency of painful crises as measured by pain diary days (analysable data available) (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). None of the oral studies reported on length of stay in hospital or quality of life (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). In reporting adverse effects, none of the studies categorised these as mild, moderate or severe as we had originally planned to report. We therefore presented adverse event data in general and not by the severity of the event. </p> <p>We were able to analyse all the primary outcomes for the studies of intravenous Mg sulphate, but the data were limited. We were not able to analyse outcomes which we expected to for oral Mg pidolate. The most common reason for this was that the interventions have so far mainly been evaluated in pilot studies instead of RCTs; these non‐randomized studies are not eligible for inclusion in our review. Furthermore, not all the outcome measures, which we defined a priori, were assessed, e.g. none of the included RCTs reported any change in dense red cells and haematological effects from Mg treatment. Although we planned to investigate whether oral Mg reduces the number of dense erythrocytes and improves the erythrocyte membrane transport abnormalities in people with SCD, we failed to do so because complete data were not reported. In the included studies, both oral Mg pidolate and intravenous Mg sulphate were given at a lower dose than the maximally‐tolerated dose, perhaps limiting our ability to identify any biological effects on red blood cell density. Our review provides a basis for performing clinical efficacy studies using oral Mg or intravenous Mg sulphate for treating SCD, which may improve painful episodes, reduce red cell dehydration and length of hospital stay. </p> </section> <section id="CD011358-sec-0105"> <h3 class="title" id="CD011358-sec-0105">Quality of the evidence</h3> <p>There is a moderate level of evidence for the change in frequency of VOCs, which demonstrated no significant difference between intravenous Mg sulphate and the control group in treating SCD. However, there is low quality evidence for the effect of intravenous Mg sulphate on length of hospital stay, adverse events (hypotension, warm at infusion site) and HRQoL (<a href="./full#CD011358-tbl-0001">summary of findings Table for the main comparison</a>). With regards to treatment with oral Mg for treating SCD, there is low quality evidence for the assessment of painful crisis and moderate quality evidence in the effects on K‐Cl co‐transport (red cell Mg content) with oral Mg (<a href="./full#CD011358-tbl-0002">summary of findings Table 2</a>). </p> <p>Four studies were judged to be at a low risk of selection bias, with adequate methods to generate a random sequence and to conceal group allocation (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>); the remaining study was judged to have an unclear risk of selection bias (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). Blinding of participants and personnel was only undertaken in four studies (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>), while we judged a single study to have an unclear risk for this domain (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). Only one study had a low risk of detection bias, where the outcome assessors were blinded (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>), the remaining studies had an unclear risk of detection bias. Two studies were judged to have an unclear risk of attrition bias (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>), one study had a high risk of attrition bias (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>) and two studies had a low risk of attrition bias (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). Three studies were judged to be at low risk of selective reporting bias as we were able to confirm that they reported on each planned outcome (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>; <a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). However, there was no available protocol for either of the remaining studies and so it was unclear if the other two studies had a risk of bias from this domain (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>; <a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> <p>We assessed sample‐size calculations of other potential sources of bias and regarded one included study as having a low risk of bias due to sample‐size calculation (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). In first study, the total numbers of participants needed per arm was stated in the protocol as being 91; however, in full article it reported that 410 people were approached to take part in the study, 208 were randomized with 204 (98%) receiving the study drug and just four (2%) not doing so. The number of participants included in analysis were 100 (99%) from one arm and 102 (99%) from the second arm. In each arm one participant (1%) withdrew with the reason given as there being no outcome data (<a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a>). Two studies were judged to have a high risk of bias relating to sample size calculations (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>; <a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). The historical changes in the study archive for the the Goldman study, give the estimated enrolment ranging from 120 to 126 participants, but the full article states that a total of 159 individuals were approached for the study, 106 (67%) consented and two participants (2%) then withdrew their consent (<a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a>). In the CHAMPS study, the original sample size calculation was 188 participants across four treatment arms, but the full article states that 64 participants were enrolled and 44 of these were randomized; only 22 participants completed 44 weeks of the study. The study was terminated early because of the slow enrolment (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). Finally, the two remaining studies was judged to have an unclear risk bias due to sample sizes; one stated that the expected sample size of 20 participants, but was terminated early due to the lack of accrual; the full article is not yet available (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). The second study has no details with regards to sample size calculations (<a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a>). </p> </section> <section id="CD011358-sec-0106"> <h3 class="title" id="CD011358-sec-0106">Potential biases in the review process</h3> <p>This review complies with the comprehensive methodology which is applicable for finding and assessing all relevant studies. We extracted information from RCTs using standard Cochrane methods for data extraction and analysis with reference to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011358-bbs2-0052" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We contacted the study authors to obtain further data when we were limited by the reported data and requested protocols of their studies to allow the inclusion and further analysis of studies. Our review has some limitations, while we were able to access the protocols of four of the included studies and their history of changes from a clinical trials registry; we were unable to obtain much of the required primary data to include in our systematic analysis. </p> </section> <section id="CD011358-sec-0107"> <h3 class="title" id="CD011358-sec-0107">Agreements and disagreements with other studies or reviews</h3> <p>There are no other reviews or studies on this topic to compare with this Cochrane Review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011358-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/urn:x-wiley:14651858:media:CD011358:CD011358-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_t/tCD011358-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011358-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011358-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/urn:x-wiley:14651858:media:CD011358:CD011358-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_t/tCD011358-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011358-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011358-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/urn:x-wiley:14651858:media:CD011358:CD011358-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_t/tCD011358-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011358-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011358-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/urn:x-wiley:14651858:media:CD011358:CD011358-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_t/tCD011358-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 1 Pain score." data-id="CD011358-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 1 Pain score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/references#CD011358-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011358-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/urn:x-wiley:14651858:media:CD011358:CD011358-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_t/tCD011358-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 2 Quality of Life (Child self‐report total score)." data-id="CD011358-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 2 Quality of Life (Child self‐report total score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/references#CD011358-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011358-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/urn:x-wiley:14651858:media:CD011358:CD011358-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_t/tCD011358-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 3 Quality of Life (Parent self‐report total score)." data-id="CD011358-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 3 Quality of Life (Parent self‐report total score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/references#CD011358-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011358-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/urn:x-wiley:14651858:media:CD011358:CD011358-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_t/tCD011358-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 4 Length of hospital stay (hours)." data-id="CD011358-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 4 Length of hospital stay (hours). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/references#CD011358-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011358-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/urn:x-wiley:14651858:media:CD011358:CD011358-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_t/tCD011358-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 5 Adverse effects (at up to 1 month)." data-id="CD011358-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Intravenous magnesium sulphate versus placebo, Outcome 5 Adverse effects (at up to 1 month). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/references#CD011358-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011358-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/urn:x-wiley:14651858:media:CD011358:CD011358-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_t/tCD011358-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral magnesium pidolate versus placebo, Outcome 1 Pain diary of days with significant pain." data-id="CD011358-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Oral magnesium pidolate versus placebo, Outcome 1 Pain diary of days with significant pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/references#CD011358-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011358-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/urn:x-wiley:14651858:media:CD011358:CD011358-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_t/tCD011358-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral magnesium pidolate versus placebo, Outcome 2 Effects on magnesium content (erythrocytes)." data-id="CD011358-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Oral magnesium pidolate versus placebo, Outcome 2 Effects on magnesium content (erythrocytes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/references#CD011358-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/media/CDSR/CD011358/image_n/nCD011358-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011358-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intravenous magnesium sulphate versus placebo for treating sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous magnesium sulphate versus placebo for treating sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : people with sickle cell disease<br/> <b>Settings</b> : emergency department (Toronto, Canada); children's hospital (USA)<br/> <b>Intervention</b>: intravenous magnesium sulphate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intravenous magnesium sulphate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in frequency of vaso‐occlusive painful crises</b> </p> <p><b>(as measured by pain diary of days with significant pain)</b> </p> <p>Follow up: Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain score in placebo group was <b>5.3</b>. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain score in the intervention group was <b>0.10 higher</b> (0.82 lower to 1.02 higher) than in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the mean pain score between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HRQoL score (Child‐reported PedsQL generic scale) at 1 week follow up</b> </p> <p>Follow up: 7‐10 days and 3 months after discharge from hospital</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HRQoL score (child‐reported HRQoL) in the intervention group was<br/> <b>2.3 lower</b> (7.21 lower to 2.61 higher) than in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the mean HRQoL score between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HRQoL score (Child‐reported PedsQL multidimensional fatigue scale) at 1 week follow up</b> </p> <p>Follow up: 7‐10 days and 3 months after discharge from hospital</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HRQoL score (child‐reported HRQoL) in the intervention group was <b>1.4 lower</b> (13.44 lower to 10.64 higher) than in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the mean HRQoL score between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HRQoL score (Child‐reported PedsQL sickle cell disease module) at 1 week follow up</b> </p> <p>Follow up: 7‐10 days and 3 months after discharge from hospital</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HRQoL score (child‐reported HRQoL) in the intervention group was 3.5<b>lower</b> (14.95 lower to 7.95 higher) than in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the mean HRQoL score between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay (hours)</b> </p> <p>Follow up: Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay in the control group was <b>117.9 hours.</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay in the intervention group was <b>14.7 higher</b> (20.51 lower to 49.91 higher) than in the placebo group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the mean length of hospital stay between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> hypotension </p> <p>Follow up: Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5</b> out of 151 participants. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2</b> out of 155 participants. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.57</b> <br/> (0.50 to 13.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in hypotension between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> warmth at infusion site </p> <p>Follow up: 7‐10 days and 3 months after discharge from hospital</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2</b> out of 102 participants. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26</b> out of 100 participants. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 13.26</b> <br/> (3.23 to 54.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was significant difference in warmth at the infusion site between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>HRQoL</b> : health‐related quality of life; <b>NA</b> : not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded due to serious limitation of risk of bias: the study lacked blinding of outcome assessment and the targeted sample size expected from protocol was not achieved.<br/> <sup>2</sup> Evidence downgraded to imprecision: wide 95% CIs of the effects of outcomes of the intervention.<br/> <sup>3</sup> Serious risk of bias: method of blinding of outcome assessment was not clearly described. Downgraded by one level from high.<br/> <sup>4</sup> The results from the study were presented as either median or mean difference so an estimate of risk within the control group is not available. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intravenous magnesium sulphate versus placebo for treating sickle cell disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011358-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral magnesium pidolate versus placebo/no intervention for treating sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral magnesium versus placebo for treating sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : people with sickle cell disease<br/> <b>Settings</b> : outpatient (Europe)<br/> <b>Intervention</b>: oral magnesium pidolate </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo/no intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Magnesium</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in frequency of vaso‐occlusive painful crises</b> </p> <p><b>(as measured by pain diary days with significant pain)</b> </p> <p>Follow up: Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of painful days in the intervention group was <b>1.9 higher</b> (1.05 lower to 4.85 higher) than in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over randomized controlled study.</p> <p>There was no significant difference in the mean number of painful days between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Length of hospital stay</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in dense red cells in sickle cell disease</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effects of K‐Cl cotransport red cell K+ and Mg2+ content (RBC magnesium) mM/kg Hb</b> </p> <p>Follow up: Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA<sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean RBC magnesium in the intervention group was <b>0.46 higher</b> (0.29 lower to 1.21 higher) than in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over randomized controlled study.</p> <p>There was no significant difference in mean RBC magnesium between the intervention group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events:</b> diarrhoea and headache </p> <p>Follow up: every 2 weeks then every 4 weeks.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 events that were considered probably related to drug (or placebo).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over randomized control study (<a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a>). </p> <p>This study reported adverse events as total for both intervention and placebo period.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events:</b> including serious adverse events, vaso‐occlusive crisis, gastrointestinal disorder, headache or migraine, upper respiratory tract infection, rash </p> <p>Follow up: 26.3 patient years of follow up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>293 adverse events while receiving study drugs.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase II multi‐centre double‐blinded trial, factorial design (<a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a>). </p> <p>This study reported adverse events for four treatment arms. No differences were observed across the four treatment groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>K‐Cl</b> : potassium chloride; <b>NA</b> : not applicable; <b>RBC</b> : red blood cell; <b>RR:</b> Risk Ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Evidence downgraded to imprecision: wide 95% CIs of the effects of outcomes of the intervention.<br/> <sup>2</sup>Evidence downgraded due to reporting bias: the study protocol was not available.<br/> <sup>3</sup>The results from the study were presented as mean difference so an estimate of risk within the control group is not available.<br/> <sup>4</sup>Evidence downgraded due to unclear risk of selection bias (random sequence generation and allocation concealment) and reporting bias.<br/> <sup>5</sup>High risk of attrition bias: incomplete outcome data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral magnesium pidolate versus placebo/no intervention for treating sickle cell disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011358-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Interventions in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial design</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011358-bbs2-0003" title="GoldmanRD , MounstephenW , Kirby‐AllenM , FriedmanJN . Intravenous magnesium sulphate for vaso‐occlusive episodes in sickle cell disease. Pediatrics2013;132(6):e1634‐41. [CENTRAL: 959808; CFGD Register: SC253a; CRS: 5500050000000103; EMBASE: 2013809378] GoldmanRD , MounstephenW , Kirby‐AllenM , MaN , FriedmanJN . Randomized double‐blind placebo controlled trial of intravenous magnesium for children with sickle cell disease vaso‐occlusive crisis ‐ The mast project. Paediatrics &amp; Child Health2011;16:17A. [CENTRAL: 1032732; CFGD Register: SC253b; CRS: 5500050000000498; EMBASE: 70784028] ">Goldman 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous Mg sulphate</p> <p>Dosage: 8‐hourly doses of 100 mg/kg, maximum of 2 g per dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo (saline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomized parallel study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] ">MAGiC 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous Mg sulphate</p> <p>Dosage: 40 mg/kg (max 2.4 g). Infused at a concentration of 40 mg/mL, 8‐hourly, total of 6 doses </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo (normal saline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomized parallel study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] ">CHAMPS 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral Mg pidolate</p> <p>Liquid</p> <p>Dosage: 0.3 mmol/kg/day in twice daily doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo or hydroxyurea</p> <p>(data from comparison of Mg versus hydroxyurea not eligible for inclusion in this review) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomized parallel study (factorial design)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011358-bbs2-0002" title="DeMontalembertM , Roudot‐ThoravalF , GalacterosF , DeFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease [abstract]. British Journal of Haematology2003;121(Suppl):43. [CENTRAL: 593125; CFGD Register: SC177a; CRS: 5500100000003076] deMontalembertM , Roudot‐ThoravalF , GalacterosF , deFranceschiL , BrugnaraC , BeuzardY . Treatment with oral magnesium pidolate in children with sickle cell disease. Blood2002;100(2):454a. [CENTRAL: 593400; CFGD Register: SC177b; CRS: 5500050000000497] ">De Montalembert 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral Mg pidolate</p> <p>Blisters containing 1500 mg of pyrolidone carboxylate of Mg</p> <p>Dosage: 1, 2, 3 or 4 blisters per day depending on weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomized cross‐over study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011358-bbs2-0005" title="MuellerBU . Oral Magnesium Pidolate, Hemoglobin SC disease, MG pidolate. NCT00040456. clinicaltrial.gov (accessed 26th March 2015). MuellerBU , DinuM , KurthS , BryantR , MullenE , YanJ , et al. The safety of oral magnesium pidolate in children with hemoglobin SC disease [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio. 2005:147. [CENTRAL: 592986; CFGD Register: SC181; CRS: 5500100000002949] ">Mueller 2005</a> </p> <p>(NCT 00040456)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral Mg pidolate</p> <p>Liquid</p> <p>Dosage: 0.6 meq Mg pidolate/kg body weight per day divided into 2 daily doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomized cross‐over study</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Mg: magnesium</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Interventions in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011358-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Length of stay (hours)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study: </b><a href="./references#CD011358-bbs2-0004" title="Badaki‐MakunO , ScottJP , PanepintoJA , CasperTC , HilleryCA , DeanJM , et al. Intravenous magnesium for pediatric sickle cell vaso‐occlusive crisis: methodological issues of a randomized controlled trial. Pediatric Blood &amp; Cancer2014;61(6):1049‐54. [CFGD Register: SC240a; CRS: 5500125000000731; PUBMED: 24443249] BrandowAM , NimmerM , SimmonsT , CasperTC , CookLJ , ScottJP , et al. Higher dose of opioids in the emergency department and earlier initiation of oral opioids after hospitalization are associated with shorter length of stay in children with sickle cell disease treated for acute pain. Blood2015;126(23):525. [CENTRAL: 1134742; CFGD Register: SC240e; CRS: 5500050000000496; EMBASE: 72171271] BrandowAM , NimmerM , SimmonsT , Charles CasperT , CookLJ , ChumpitaziCE , et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology2016;91(12):1175‐80. [CFGD Register: SC240h; CRS: 5500135000001642; PUBMED: 27517842] BrousseauDC , ScottJP , BadakiO , DarbariDS , ChumpitaziC , AireweleGE , et al. A multi‐center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children [abstract]. Blood2014;124(21):Abstract no: 88. [CFGD Register: SC240c; CRS: 5500135000001417] BrousseauDC , ScottJP , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood2015;126(14):1651‐7. [CFGD Register: SC240d; CRS: 24443249; DOI: 10.1182/blood‐2015‐05‐647107] EsteppJH . MAGiC: VOC remains but kids with SCA appear. Blood2015;126(14):1637‐8. [CFGD Register: SC240f; CRS: 5500135000001643; PUBMED: 26429963] HulbertML , PanepintoJA , ScottJP , LiemRI , CookLJ , SimmonsT , et al. Red blood cell transfusions during sickle cell anemia vaso‐occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion2017;57(8):1891‐7. [CFGD Register: SC240i] McArdleJ , TillerG . Intravenous magnesium not effective in sickle cell pain crises. Journal of Paediatrics and Child Health2016;52(10):970. [CENTRAL: 1215835; CFGD Register: SC240g; CRS: 5500135000001641; PUBMED: 27739204] PanepintoJA , BeverungLM , CasperTC , CookLJ , BrousseauDC . The impact of an acute vaso‐occlusive crisis on patient reported outcomes: the MAGIC study [abstract]. Blood2014;124(21):441. [CFGD Register: SC240b; CRS: 5500135000001416] PanepintoJA , Paul ScottJ , Badaki‐MakunO , DarbariDS , ChumpitaziCE , AireweleGE , et al. Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL Sickle Cell Disease Module. Health and Quality of Life Outcomes2017;15(1):124. [CFGD Register: SC240j] "><b>MAGiC 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Magnesium Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOS: median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.0 (27.0 ‐ 109.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.0 (24.0 ‐ 99.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOS: total time until discharge from hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.5 (40.0 ‐ 124.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.5 (37.0 ‐ 122.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOS: early in the course of the pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.0 (30.0 ‐ 113.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.0 (23.0 ‐ 92.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.49</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>IQR: interquartile range<br/> LOS: length of stay </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Length of stay (hours)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011358-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Effects on K‐Cl cotransport, red cell K+ and Mg2+ content</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Study: </b><a href="./references#CD011358-bbs2-0001" title="WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology2011;152(6):771‐6. [CENTRAL: 801819; CFGD Register: SC210b; CRS: 5500125000000521; PUBMED: 21275961] WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the &quot;CHAMPS'trial [abstract]. Blood2009;114(22):Abstract no:819. [CENTRAL: 744106; CFGD Register: SC210a; CRS: 5500100000003436] "><b>CHAMPS 2011</b> </a> </p> <p><b>Ion content</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>No Mg</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>N (minimum, maximum)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>N (minimum, maximum)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(20, 23)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(13, 17)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(12, 13)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(19, 21)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(17, 19)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>(13, 14)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Week 8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Week 24</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Week 8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Week 24</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plasma ionized Mg (mmol/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plasma total Mg (mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>K‐Cl co‐transport (mmol/10<sup>13</sup>cells x h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cell Na (mmol/kg Hb)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cell K (mmol/kg Hb)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>236</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Both mean levels of plasma ionised Mg and plasma total Mg at week 8 were slightly greater compared to placebo (P value = 0.02 for ionised Mg) (P value = 0.04 for total Mg). </p> <p>Cl: chloride<br/> Hb: haemoglobin<br/> K: potassium<br/> Mg: magnesium<br/> Na: sodium </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Effects on K‐Cl cotransport, red cell K+ and Mg2+ content</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/full#CD011358-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011358-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravenous magnesium sulphate versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.82, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of Life (Child self‐report total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Child self‐reported PedsQL Generic Scales (Pre‐discharge)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [‐37.50, 40.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Child self‐reported PedsQL Generic Scales (1 week follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.3 [‐7.21, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Child self‐reported PedsQL Multidimensional Fatigue Scales (Pre‐discharge)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.8 [‐2.06, 7.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Child self‐reported PedsQL Multidimensional Fatigue Scales (1 week follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.4 [‐13.44, 10.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Child self‐reported PedsQL Sickle Cell Disease Module (Pre‐discharge)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.20 [‐7.75, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Child self‐reported PedsQL Sickle Cell Disease Module (1 week follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.5 [‐14.95, 7.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of Life (Parent self‐report total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Parent self‐reported PedsQL Generic Scales (Pre‐discharge)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.4 [‐12.17, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Parent self‐reported PedsQL Generic Scales (1 week follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐6.85, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Parent self‐reported PedsQL Multidimensional Fatigue Scales (Pre‐discharge)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.7 [‐7.79, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Parent self‐reported PedsQL Multidimensional Fatigue Scales (1 week follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐2.87, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Parent self‐reported PedsQL Sickle Cell Disease Module (Pre‐discharge)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.4 [‐4.88, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Parent self‐reported PedsQL Sickle Cell Disease Module (1 week follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.4 [‐1.85, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Length of hospital stay (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.70 [‐20.51, 49.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects (at up to 1 month) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nausea or vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.15, 7.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.50, 13.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Pain at the infusion site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.64 [0.79, 16.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Warmth at the infusion site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.26 [3.23, 54.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.13, 74.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Acute chest syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.60, 2.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravenous magnesium sulphate versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/references#CD011358-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011358-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral magnesium pidolate versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain diary of days with significant pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Effects on magnesium content (erythrocytes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral magnesium pidolate versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011358.pub3/references#CD011358-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011358.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011358-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011358-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011358-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011358-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD011358-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD011358-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011358-note-0001">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011358-note-0015">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011358\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011358\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011358\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011358\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011358\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011358.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011358.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011358.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011358.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011358.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724534213"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011358.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724534217"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011358.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e651fbb83f44a',t:'MTc0MDcyNDUzNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 